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ABSTRACT
RNA SPLICING IN NEURON PHYSIOLOGY AND
NEURODEGENERATIVE DISEASES
Md Faruk Hossain
Gene expression is regulated at multiple levels, including transcription, RNA
editing, pre-mRNA splicing, mRNA export, translation, and posttranslational
modifications. Alternative splicing is a process by which exons can be included or
excluded, giving rise to multiple mRNA isoforms from the same transcript. Alternative
splicing is an important mechanism in developmental, tissue- and cell-specific control of
gene expression, and it is key for expanding proteomic diversity and complexity from a
limited number of genes. Moreover, more than 95% of multiexon genes undergo
alternative splicing in humans, and about half of all disease-causing point mutations in
humans affect pre-mRNA splicing, including neurological disorders and cancer. The
central nervous system comprises the tissues and cells with the highest rate of alternative
splicing in the body, and RNA-binding proteins play a major functional role in neurons.
However, the regulatory mechanisms of splicing are still poorly understood. This
dissertation specifically aims to advance the understanding of regulatory mechanism of
pre-mRNA splicing. To this end, we collaboratively performed two projects.
In the first project, we investigated how NOVA, a neuron-specific splicing factor,
regulates nerve cell-specific alternative splicing of Z+ Agrin — a molecule that is the
master architect of nerve-muscle synapses at the neuromuscular junction (NMJ). We
cloned the Ciona ortholog of NOVA, which is present as a single copy gene in tunicates,
and that of Agrin, and dissected the regulatory mechanism of alternative splicing of Z +

Agrin by Nova. Moreover, we characterized their function and expression pattern during
larval development, which we will discuss in detail in Chapter 2 of this dissertation.
The second project was a case study where we investigated how mutations in the
SLC25A10 gene cause epileptic encephalopathy by disrupting pre-mRNA splicing.
SLC25A10 codes for a solute carrier protein and is a part of complex I in mitochondria.
The patient inherited 3 mutations: 1 from the mother and 2 from the father. The maternalderived mutation introduces a stop codon in exon 3. Mutations from the paternal allele
are located in exon 9 and intron 10. Although the exonic mutation is a synonymous
mutation, the patient had very low levels of SLC25A10 mRNA and lacked protein at
detectable levels. Using minigene splicing assay we investigated the molecular
mechanism underlying disease pathology in the patient. In Chapter 3 of this dissertation,
we will discuss how paternal-derived mutations lead to aberrant splicing.
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CHAPTER 1
INTRODUCTION
The focus towards the understanding of gene expression regulation largely shifted
after the completion of human genome sequencing projects. Gene regulation is a set of
complex biological processes that help genetic information to flow from DNA to RNA to
proteins, which is known as the central dogma of biology. Gene regulation involves
several processes involving chromatin remodeling, transcription, post-transcriptional
regulation (pre-mRNA splicing/alternative splicing), mRNA export and editing,
translation, and posttranslational modifications. Alternative splicing (AS) is one of the
most critical steps in gene regulation, which results in multiple proteins with often
distinct functions from a single gene. Compared with other tissue types, AS is highly
abundant in the brain. Emerging evidence has shown that the disruption of AS plays a
significant role in many human diseases, including cancer, diabetes, and
neurodegenerative diseases. In this dissertation, we show the importance of pre-mRNA
splicing in neuron physiology and neurodegenerative disorders. This chapter gives a brief
introduction and background information related to splicing and its role in neurological
disorders.

1.1 Gene splicing and alternative splicing
Gene expression is regulated at multiple levels, including transcription, RNA
editing, pre-mRNA splicing, mRNA export, translation, and posttranslational
modifications. After a gene is transcribed into pre-mRNAs, introns are spliced out and
1

exons are joined together to make mature mRNA transcript(s) in a process called premRNA splicing. Pre-mRNA splicing was first detected in adenovirus in the 1970s (Chow
el al., 1977; Berget el al., 1977) and later splicing was discovered in all eukaryotes,
including yeast, plants, and animals. While constitutive pre-mRNA splicing produces a
single transcript from a gene, AS on the other hand produces multiple mRNA from the
same pre-mRNA transcript by specifically including or excluding alternative exon(s).
Approximately 95% multiexonic human genes undergo AS (Gilbert, 1978; Pan et al.,
2008). In fact, AS mechanism explains the tremendous number of protein variants from a
limited repertoire of ~25,000 genes in human and is a major source of proteomic
diversity and complexity (Pan et al., 2008). One of the noticeable examples of proteomic
diversity by AS is the Drosophila Dscam gene. Dscam is a member of the
immunoglobulin superfamily required for axon guidance (Schmucker et al., 2000) and
through 95 alternative exons has the potential to generate 38,016 distinct axon guidance
receptors. That is a staggering number of different isoforms originating from a single
gene that exceeds the total number of genes present in the Drosophila genome (Misra et
al., 2002).

1.2 The classification of alternative splicing
In eukaryotes, several different functional protein isoforms can be produced by
AS. The regulation of AS depends on a combination of tissue-specific and universally
expressed trans-acting RNA-binding factors that interact with cis-acting elements on the
pre-mRNA molecule. Precise AS regulation is biologically and physiologically important
for normal development. The completion of genome sequencing has provided important
insights into the various modalities of pre-mRNA splicing. There are seven major types
2

of AS described so far. About 40% of the AS type is the skipped exon (SE), also known
as cassette exon (Sugnet et al., 2004; Kim et al., 2007). Cassette exons can be included or
excluded in the mature mRNA. Multiple cassette exons give rise to another splicing
pattern known as mutually exclusive cassette exons. In this case the final processed
mRNAs always include only one of the available alternative exon cassettes. Another two
types of splicing modalities are the lengthening or shortening of an exon with the
differential use of alternative 5’ and alternative 3’ splice sites. The regulatory potential of
AS can be expanded by two other modalities where alternative polyadenylation sites and
alternative promoter sites can be utilized. In another mode of AS, the intron can be
included in the mature mRNA and the process is called intron retention. Moreover, AS
can be combinatorial – meaning that multiple modes of the above-mentioned AS events
can be observed in the mature mRNA (Black et al., 2003).

1.3 The splicing machinery and regulatory network of alternative
splicing
Constitutive splicing and AS are strictly controlled by complex interactions of
many cis-regulatory elements and trans-acting RNA-binding proteins (RBPs). Splicing is
performed by a large and dynamic complex called the spliceosome that is composed of
small ribonucleoprotein particles (snRNPs). The splicesome core is composed of four
small ribonucleoprotein particles (snRNP U1, U2, U4/U6 and U5) and numerous
auxiliary proteins that are assembled together to execute a series of steps involved in
splicing, including looping the intron, excising the intron, and joining the exons. Mass
spectrometric analysis revealed that the spliceosome is one of the largest protein
complexes in mammals and it is assembled by more than 300 proteins (Burge et al.,
3

1999; Zhou et al., 2002; Barbosa-Morais et al., 2006;). The fundamental splicing signals
are universal; however, the level of conservation varies in different exons/introns and
organisms. Each intron is almost invariantly marked by a GU dinucleotide at the 5’ end
(5’ splice site, or 5’ss), and an AG dinucleotide at the 3’end (3’ splice site or 3’ss).
Moreover, a branch point sequence (BPS) upstream of the 3’ss and a polypyrimidine tract
between the BPS and the 3’ss are other important signals. Normally, constitutive exons
tend to have strong 5’ and 3’ ss, while alternative exons have relatively weaker 5’ and 3’
ss, therefore other RNA-binding proteins play a critical role on splice sites recognition
(Stamm et al., 1994).
RBPs/splicing factors act together with the spliceosome to from extensive proteinprotein and protein-RNA complexes to control the expression of functionally distinct
isoforms in specific tissues and developmental stages by promoting or blocking the
inclusion of alternative exon(s) in the final processed mRNAs. While the spliceosome
acts on the primary splicing signals (exon-intron junction, branchpoint A site in the
intron, and intron-exon junction) to perform splicing, RBPs act on cis-acting specific
sequences either in exons or in introns to execute AS. Cis-acting sequences on premRNA are generally divided into four categories: exonic splicing enhancers and silencers
(ESEs and ESSs), and intronic splicing enhancers and silencers (ISEs and ISSs) (Cartegni
et al., 2002). Interactions between the cis-acting regulatory elements and trans-acting
splicing factors determine splicing outcome. RBPs are key regulators of AS, and their
expression is often developmentally regulated and also tissue-specific. RBPS are of two
types: AS activators and AS repressors. For instance, SR proteins promote inclusion of
alternative exon(s) by binding to ESEs (Shen et al., 2004) and heterogeneous
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ribonucleoproteins (hnRNPs) block inclusion of alternative exon(s) when bound to ESSs
(Del Gatto-Konczak et al, 1999). There are about 1,000 RBPs in the human genome with
approximately 40 different types of RNA-binding motifs, including RNA-recognition
motifs, K-homology (KH) domains etc (Lunde et al., 2007). Expression of RBPs is often
cell- or tissue-type specific. They can be expressed in different combinations to increase
proteomic diversity, and they often have multiple target genes. Subsequently, aberrant
expression or disrupting the function of a single RBP often affects posttranscriptional
regulation of numerous pre-mRNA transcripts, a phenomenon frequently reported in
human diseases associated with RBPs.

1.4 The role of alternative splicing in neuron physiology
Previous studies clearly showed that there is extensive AS regulation across brain
regions and across developmental stages (Dillman et al., 2013). Moreover, compared to
other cell types neurons have the highest number of alternative exons, thus producing a
greatest diversity of protein isoforms compared to other tissues (Porter et al., 2018). For
example, neurons generate neurotransmitter receptors with different specificities and
coordinates the activity of protein networks at the synapse (Ule et al., 2005). The voltagegated Ca2+ channels (VGCCs) in the presynaptic terminal are key determinants of celland synapse-specific neurotransmitter release properties, and the genes encoding VGCC
subunits have the potential to generate thousands of splice variants (Lipscombe et al.,
2013). For instance, AS of two mutually exclusive alternative exons (37a and 37b) in the
Cav2.1 (the so-called P/Q-type Calcium channel) α1 subunit demonstrate acute shift of
neuronal network activity, while one isoform promotes synaptic depression, the other
drives synaptic facilitation (Thalhammer et al., 2017).
5

The NMJ, possibly the best-understood mammalian synapse, is developed,
formed, and maintained by a large number of molecules that enable precise signal
transmission from spinal motor neurons to skeletal muscle. According to RefSeq gene
annotation database which adopts only experimentally-proven splicing isoforms, 8 out of
16 genes (ACHE, AGRN, CHAT, CHRNA1, CHRNB1, CHRND, CHRNE, CHRNG,
COLQ, DOK7, LAMB2, LRP4, MUSK, RAPSN, SCN4A, and SYT2) expressed at the
NMJ are alternatively spliced (O’Leary et al., 2016). According to the most extensive
AceView gene annotation database (Thierry-Mieg and Thierry-Mieg, 2006), 13 of the 16
NMJ genes are alternatively spliced, whereas CHRNE, CHRNG, and SCN4A are not. In
this dissertation, we will discuss the role of AGRN in NMJ development, formation, and
maintenance and our investigation of regulatory mechanism of AS of AGRN by NOVA
(see chapter 2 for detail).

1.5 Aberrant splicing in neurodegenerative disorders
The central nervous system comprises the tissues and cells with the highest rate of
AS in the body (Xu et al., 2002), and RBPs play a major functional role in neurons
(Lenzken et al., 2014), highlighting the critical importance of RBPs and splicing in
human biology and disease pathogenesis. Moreover, up to 50% of all disease-causing
mutations affect pre-mRNA splicing, including many cancers and neurodegenerative
disorders (Teraoka et al., 1999; Ars et al., 2003) including, Alzheimer’s disease (AD),
Parkinson’s disease (PD), Huntington’s disease (HD), Spinal Muscular Atrophy (SMA),
and Congenital Myasthenic Syndrome (CMS). Pre-mRNA splicing is disrupted in a large
number of genes in AD patients (PSEN1, PSEN2, GRN, APP, APOE, BACE, PIN1, and
MAPT), in PD patients (PARK2, SNCA, SRRM2), in HD patients (BDNF) (reviewed in
6

Mills and Janitz, 2012). To date, 30 genes (reviewed in McMacken et al., 2017) have
been reported to be CMS-related genes, many of those genes display abnormal AS
including CHRNE, DOK7, CHRNA1, RAPSAN, and COLQ genes (reviewed in Rahman
et al., 2015). AS dysregulation has been recently reported in autism spectrum disorders
(Irimia et al., 2014; Parikshak et al., 2016; Quesnel-Vallieres et al., 2016; Xiong et al.,
2015) and schizophrenia (Cai et al., 2020).
Pre-mRNA splicing patterns can be affected by mutations in splice sites, cisregulatory elements, or trans-acting RBPs. An interesting example is the skipping of
exon 7 of survival of motor neuron 2 (SMN2) due to a single nucleotide (nt)
polymorphism (C to T) at position 6 that disrupts an ESE element recognized by
SF2/ASF (Pellizzoni et al., 1998; Cartegni and Krainer, 2002), and creates an ESS
element recognized by hnRNP A1 (Kashima et al., 2003). SMA is a devastating
autosomal-recessive disorder associated with low expression levels of SMN1 protein due
to homologous deletion or disruption of SMN1. SMN2, which is an almost identical copy
of SMN1 produces a truncated isoform lacking exon 7 which is unstable and
nonfunctional (Khoo et al., 2009; Lorson et al., 1998; Lorson et al., 1999; Burnett et al.,
2009). In Mattioli et al. (2020), 6 individuals have been reported with a de novo
frameshift mutation in the RNA-binding protein NOVA2 that results in a common Cterminal extension. All 6 of the individuals are affected by a severe form of
neurodevelopment disorders. Using zebrafish ortholog of NOVA2, they have shown that
downregulation of NOVA2 affects neurite outgrowth. Moreover, downregulation of
NOVA2 alters the splicing of 41 genes in human neural cells. In chapter 3 of this
dissertation, we will discuss a case study where we investigated aberrant splicing of the
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SLC25A10 gene and explained disease pathology in a patient with epileptic
encephalopathy.
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CHAPTER 2

A CONSERVED NOVA-DEPENDENT
ALTERNATIVE SPLICING PROGRAM CONTROLS
NEUROMUSCULAR JUNCTION FUNCTION IN
THE TUNICATE CIONA ROBUSTA
2.1 ABSTRACT
Tunicates are marine invertebrates and are the closest living relatives to
vertebrates. The swimming larva of the tunicate Ciona robusta is an emerging animal
model to study developmental and evolutionary biology. Its nervous system is comprised
of a mere 177 neurons distributed rostro-caudally in a brain vesicle, a motor ganglion,
and a nerve cord and its larval connectome has been completely mapped. Due to its small
size, cellular simplicity, rapid development, and compact genome that has not undergone
the duplications seen in vertebrates, Ciona is particularly amenable to molecular
perturbation and imaging. Here we show that Ciona can be a powerful model organism to
study NMJ biology and neurodegenerative and neuromuscular disorders, including
congenital myasthenic syndrome (CMS).
NOVA1 and NOVA2 are neuron-specific AS factors and are target antigens in
patients with an autoimmune neurodegenerative disorder. One of the targets of NOVA is
a neuron-specific splice form of the ubiquitously expressed gene AGRIN. Termed Z+
AGRIN, this splice variant activates the MuSK signaling pathway by interacting with the
transmembrane receptor LRP4, thus promoting clustering of acetylcholine receptors
9

(AChRs) at the postsynaptic terminal., Interestingly, AGRIN mutations that mimic ZAGRIN cause CMS.
We cloned the Ciona ortholog of NOVA, which is present as a single copy gene in
tunicates, and that of Agrin, and characterized their function and expression pattern
during larval development. We discovered that, as in vertebrates, Ciona Agrin (CiAgrin)
also undergoes AS to generate the Z+ isoforms in Ciona, indicating that the Nova-AgrinLrp4 pathway for AChR clustering at the NMJ is shared between tunicates and mammals.
Nova harbors 3 KH-type RNA-binding domains and specifically recognizes YCAY
clusters on pre-mRNA. Ciona Nova (CiNova) requires the first two KH domains to
mediate Z exon inclusion, and it does so via a bipartite intronic splicing enhancer
downstream of the Z exons.
We also determined that at least two consecutive YCAY repeats from any of the
two clusters are needed to promote exon inclusion at Z site. Moreover, we discovered
unique function of the N/C-terminus and the KH3 domain of CiNova. It appears that, in
Ciona, the KH3 domain is a negative regulator of AS and both N- and C- terminus act
together to inhibit the negative action of KH3. We discovered that CRISPR KO of
CiNova and CiAgrin phenocopies the findings in Nova and Agrin KO mice by drastically
reducing the number of AChRs clusters at the NMJ. We provide evidence that the neuralspecific AS program of Z+ Agrin is conserved between tunicates and mammals, showing
for the first time that Ciona can be a powerful organism to study the biology of
neurodegenerative and neuromuscular disorders.

10

2.2 BACKGROUND
2.2.1 The NOVA protein family and its role in brain physiology
In mammals, the NOVA family is comprised of two highly homologous proteins
encoded by two genes (NOVA1 and NOVA2), which were first discovered as antigens in
Paraplastic Opsoclonus Myoclonus Ataxia (POMA)- a manifestation of abnormal motor
control at the level of brainstem and spinal cord (Darnell et al., 1996; Buckanovich et al.,
1996; Buckanovich et al., 1997). NOVA are neuron-specific AS factors that regulate the
AS of neuronal pre-mRNA transcripts (such as transcripts of the AGRN gene) in the
central nervous system (Buckanovich et al., 1996; Buckanovich et al., 1997). Both
NOVA1 and NOVA2 possess three K-homology (KH) RNA-binding domains (KH1,
KH2 and KH3) and it appears that it is the third KH domain (KH3) that specifically binds
to YCAY motifs on pre-mRNA transcripts to regulate inclusion or skipping of specific
alternative exons (Buckanovich et al., 1997; Jensen et al., 2000). Consistently, de novo
frameshift mutations that ablate this RNA-binding domain abolish the pre-mRNAbinding activity of NOVA (Mattioli et al., 2020).
In the central nervous system, Nova1 and Nova2 are expressed reciprocally, with
Nova2 being highly expressed in the cortex and hippocampus, while Nova1 is highly
expressed in midbrain and spinal cord (Yang et al., 1998; Saito et al., 2016). Moreover,
Nova1 is highly expressed in the ventral spinal cord while Nova2 is highly expressed in
the dorsal spinal cord (Buckanovich et al., 1997). Both Nova1 and Nova2 are also
expressed in white adipocytes (Vernia et al., 2016). The finding that there are about 700
identified Nova1/Nova2 alternate exon targets on neuron-specific pre-mRNA (Zhang et
al., 2010), is a strong pointer to the role of both Nova1 and Nova2 in the regulation of AS
of neuron-specific RNA transcripts (Saito et al., 2016). Nova1 and Nova2 possess nearly
11

identical RNA-binding domains, and both recognize the same YCAY sequence on premRNA (Buckanovich et al., 1997; Jensen et al., 2000; Sugimoto et al., 2012). These two
splicing regulators can therefore interact with and regulate AS on the same pre-mRNA
transcript (Saito et al., 2016). About 80% of the binding sites of Nova2 on pre-mRNA are
found on introns, implying a preferential binding of this splicing regulator to introns,
while Nova1 targets are almost equally distributed in introns and exons (Saito et al.,
2016). This spatial distribution of the RNA-binding targets suggests a possible
mechanistic difference in the AS events driven by these two Nova homologues (Saito et
al., 2016).
The distinct expression pattern of Nova1 and Nova2 denotes that each of these
splicing regulators appears to have a unique role in different brain areas and different
neuronal cell types (Saito et al., 2016). In the brain cortex, where Nova2 is highly
expressed, a total of 60 transcripts were significantly changed by Nova2 loss of function,
while only 2 transcripts were altered in the brain cortex by Nova1 loss of function (Saito
et al., 2016). This scenario could be partially explained by the low expression levels of
Nova1 in brain cortex. In the midbrain and hindbrain region of E18.5 mice, where Nova1
is highly expressed, 119 Nova1-dependent AS events were changed by loss of gene
function (Saito et al., 2016). Moreover, in these brain regions, only one AS event (Robo2
exon 6b), common to both Nova1 and Nova2 was slightly altered (Saito et al., 2016).
Nova proteins-mediated splicing regulation plays a critical role in the
development of the central nervous system (Leggere et al., 2016; Saito et al., 2016). The
splicing regulatory role of Nova proteins has been implicated in neuronal migration in
both cortical neurons and Purkinje neurons (Yano et al., 2010). Nova2 is also important
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for the induction of long-term potentiation of slow inhibitory post synaptic current in
hippocampus neurons (Huang et al., 2005). In addition to the above-mentioned Novamediated roles, four research articles (Ruggiu et al., 2009; Leggere et al., 2016; Saito et
al., 2016; and Saito et al., 2019) expand the knowledgebase on the functional role of
Nova family proteins in the development of the central nervous system. The AS outcome
of Nova proteins is based on their binding position on the target pre-mRNA (Dredge et
al., 2005; Allen et al., 2010). Nova proteins binding to their binding sites upstream or
within an alternative exon represses exon inclusion (Dredge et al., 2005). In contrast,
Nova-mediated effect on alternative exon inclusion enhancement can be attributed to
binding of the Nova protein downstream of an alternative exon (Dredge et al., 2005). In
addition, the Nova-mediated splicing effect on alternate exon inclusion may be due to its
blocking of the binding of both essential splicing factors like U1 snRNP, and nonessential splicing factors like SR proteins, onto the pre-mRNA transcript (Dredge et al.,
2005). Nova2 expression is down regulated by the RE-1-Silencing Transcription factor
(REST), a transcription repressor that is highly expressed in non-neuronal cells and early
embryonic neuronal cells but is silenced in mature differentiated neuronal cells (Mikulak
et al., 2012). On the contrary, Nova1 expression does not appear to be regulated by REST
in both neuronal and non-neuronal cells (Mikulak et al., 2012).
2.2.2 Functions of Nova1
Nova1 is highly expressed in midbrain and ventral spinal cord (Yang et al., 1998;
Saito et al., 2016) but is also expressed in non-neuronal cells, with high expression in
pancreatic beta cells (at levels comparable to brain) and white adipose tissue, and low
expression in the cervix, colon, muscle cells, liver, spleen, and lungs (Eizirik et al., 2012;
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Villate et al., 2014; Meldolesi et al., 2020; Vernia et al., 2016). Although Nova1 null
(Nova1-/-) mice in Jensen et al. (2000) were indistinguishable from their littermates, they
died postnatally due to a progressive motor defect caused by increased apoptotic death of
spinal and brainstem neurons. In Ruggiu et al. (2009), Nova1-/- mice lacked defects in
Agrin Z+ AS in brain and spinal cord, and in AChR clustering or neuromuscular
innervation at the NMJ. Nova1-/- mice in Saito et al., 2016 did not portray any defects in
neuronal development. They had normal parameters in dorsal interneuron development
and differentiation, axon outgrowth and corpus callosum (CC) formation. In addition,
these mutant mice lacked the defects displayed by Nova2-/- mice in both ventral
diaphragmatic and auditory efferent innervation (Saito et al., 2016; Leggere et al., 2016).
Nova1 does not appear to have a regulatory role in the axon guidance process in
the brain cortex (Saito et al., 2016). Specifically, Nova1 does not appear to regulate the
AS of key exons in axon guidance-related genes, including: Dcc exon 17, Slit2 exon 28b,
Robo2 exons 6b and 21, Epha5 exon 7, Arhgef12 exon 4, Ppp3cb exon 10b, Neo1 exon
26, and Rock1 exon 27b (Saito et al., 2016). The missing regulatory role of Nova1 in the
brain cortex could however be due to the low expression levels of Nova1 in the brain
cortex. It would be interesting to observe the effects of Nova1 overexpression in the brain
cortex.
Nova1 is an enhancer of exon inclusion during AS. For example, Nova1 enhances
the inclusion of exon 9 during the AS of the gamma-aminobutyric acid A receptor,
gamma 2 subunit (Gabrg2) pre-mRNA in the brain and human pancreatic islets (Eizirik et
al., 2012; Dredge and Darnell, 2003; Jensen et al., 2000a). Nova1 also enhances the
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inclusion of exon 3A (E3A) during AS of the of glycine receptor a2 (GlyRα2) pre-mRNA
(Jensen et al., 2000a; Polydorides et al., 2000).
In pancreatic cells, Nova1 has a functional role in both transcription and AS
regulation, but its role is more pronounced in splicing regulation (Villate et al., 2014). In
these cells, Nova1 is a master regulator of the AS of 4961 isoforms, involved in a wide
array of cellular functions, including: apoptosis, insulin receptor signaling, exocytosis,
transcription regulation, and cell signaling (Villate et al., 2014). Examples of Nova1regulated genes in pancreatic cells include apoptosis genes (Casp3, Apaf1), insulin
receptor signaling genes (INSR, FoxO1), calcium signaling genes (Cacna1b, Cacna1c,
Cacna1d), exocytosis genes (Apba1, Cadps, Cdc42, Gnai3, Snap25), transcription
regulation genes (Pax6, FoxO1, FoxO3) and some other cell signaling genes (Villate et
al., 2014).
The high expression of Nova1 in both the brain and pancreatic islets denotes a
common splicing regulatory role and a common mechanism of action in these two
organs. For example, the exocytosis process of neurotransmitter release in the neurons is
similar to that of insulin release from pancreatic beta cells (Juan-Mateu et al., 2017). In
fact, 80% of Nova1-regulated genes are highly expressed in both the brain and pancreatic
beta cells (Villate et al., 2014). Examples of these genes are: Gabrg2, Neuroligin and
Neurexin family members, inhibitory synapse-associated neuroligin and neurexin binding
partners (Villate et al., 2014; Eizirik et al., 2012). The mechanism of Nova1 splicing
regulation appears to be similar in both the brain and pancreatic beta cells (Villate et al.,
2014).
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In pancreatic beta cells, Nova1 also regulates the in vitro splicing of several
calcium channels proteins, including the alpha-1b, alpha-1c, alpha-1d subunits of the
voltage-dependent N-type calcium channel (Cacna1b, Cacna1c, Cacna1d) mRNA (Villate
et al., 2014). On the contrary, the splicing regulation of calcium channel proteins in the
brain is regulated by Nova2 (Allen et al., 2010). In the brain, Nova2 enhances the
inclusion of exon 24a in Cacna1a (CaV2.1) and Cacna1b (CaV2.2), but also represses the
inclusion of exon 31a in both CaV2.1 and CaV2.2 mRNA (Allen et al., 2010).
Nova1 loss of function in pancreatic cells decreases voltage-dependent calcium
current due to splicing defects in the calcium channels transcripts and thus downregulates
calcium signaling-mediated insulin exocytosis (Villate et al., 2014). In addition, Nova1
splicing action on insulin secretion genes (phospholipase PLCβ1 and the vesicle fusion
protein SNAP25) also regulates insulin secretion (Villate et al., 2014). Specifically,
Nova1-mediated effect on insulin secretion entails the AS of the exon b-containing
isoform of PLCβ1 (PLCβ1b) and enhances the inclusion of alternative exon 5b of
SNAP25 pre-mRNA during AS (Villate et al., 2014).
2.2.3 Functions of Nova2
Nova2 is highly expressed in the cortex and hippocampus regions of the brain
(Saito et al., 2016) and is sequentially expressed in a dorsal-ventral manner in the spinal
cord, with the greatest expression in the dorsal spinal cord, although the large motor
neurons of the ventral spinal cord express significant levels of both Nova1 and Nova2
(Yang et al., 1998). In non-neuronal cells, Nova2 is expressed in the lungs (Meldolesi
2020; Yang et al., 1998), endothelial cells (Giampietro et al., 2015), and in white
adipocytes (Vernia et al., 2016).
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Reduced expression of Nova2 (haploinsufficiency) leads to spontaneous epilepsy
(Eom et al., 2013). Five de novo NOVA2 mutations (2 deletions, 1 insertion, and 2
duplications) and 1 deletion mutation not present in the mother, in the last and largest
exon of NOVA2 are implicated in a serious neuro-developmental disorder characterized
by motor delay, speech delay, brain malfunction, seizures, CC thinning, hypotonia and
feeding difficulties (Mattioli et al., 2020). These mutations cause a frameshift at the
mutation site of the fourth coding exon, that results in a long C‐terminal (134 amino acids
long) tail and the loss of the third KH (KH3) domain, in the stably expressed NOVA2
protein (Mattioli et al., 2018).
Nova2 knock out (Nova2-/-) mice in Ruggiu et al., 2019 had minimal defects in Z+
Agrin splicing in both the brain and spinal cord, AChR clustering or neuromuscular
innervation in the motor neurons of the spinal cord. On the contrary, Nova2 in Saito et
al., 2016, had a profound splicing regulatory role in the brain cortex, and although
Nova2-/- mice were similar in phenotype to their littermates at birth in this study, they
died in less than three weeks due to progressive motor dysfunction.
Nova2 has a profound role in the development of the brain cortex and is integral
for axon pathfinding and outgrowth in cortical CC axons (Leggere et al., 2016; (Mattioli
et al., 2020). Nova2 is also required in the formation and extension of axonal tracts in the
brain (Mattioli et al., 2020). Nova2 expression increases gradually during mouse
development from E12.5 to E18.5 (Saito et al., 2016), with high expression in the cortical
plate and subplate (a region where post-mitotic neurons are found at E18.5 in high
numbers), implying a developmental regulation role in neural progenitor cells
differentiation (Saito et al., 2016).

17

The role of Nova2 in this developmental process is related to the AS of five axon
guidance-related genes: Dcc, Robo2, Epha5, Slit2, and Neo1, in which the loss of
function of Nova2 results in the aberrant inclusion of developmentally-regulated exons
into these axon guidance gene transcripts (Saito et al., 2016). Although Nova2 is highly
expressed in the dorsal spinal cord (Yang et al., 1998; Saito et al., 2016), its splicing
regulatory effect is only evident in motor neurons innervating the ventral diaphragm
muscles and auditory efferent axons (Saito et al., 2016). Nova2 regulates the AS of key
genes involved in neurogenesis (Mattioli et al., 2018). For example, it promotes inclusion
of exon 26 of Neogenin1 (NEO1) and represses the inclusion of exon 14 of Amyloid Beta
A4 Precursor‐ like protein 2 (APLP2). Both NOVA2 silencing and frameshift mutations
affecting the last exon of NOVA2 (Mattioli et al., 2020; Mattioli et al., 2018) perturb the
Nova2-mediated splicing events of these two genes in in vitro models (Mattioli et al.,
2020; Mattioli et al., 2018). The loss of NOVA2 function greatly affects axonal formation
and synapse function in both in vivo and in vitro settings (Mattioli et al., 2020; Mattioli et
al., 2018; Ruggiu et al., 2009). Important to note is that the mutant NOVA2 variants
(specifically Mut1) and the wild type NOVA2 counterpart had a comparable effect in
axonal outgrowth in vivo (Mattioli et al., 2020). This might be attributed to the dominant
effect of the non-mutated allele (Mattioli et al., 2020), a notion that can be further
supported by the finding that human Mut1 NOVA2 (mutant variant 1) alone could not
rescue the splicing defects caused by NOVA2 orthologue silencing in zebrafish but could
do so when injected together with wild type NOVA2 mRNA (Mattioli et al., 2020).
The axon guidance regulation of Nova2 in the brain cortex appears to be
attributed to the developmentally-regulated AS of two netrin receptors: Dcc exon 17 (Dcc
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long) and Neo1 exon 27 (Saito et al., 2016). In the spinal cord however, the dual action
of Nova1 and Nova2 is required for the regulation of Dcc exon 17 in the developing
spinal commissural neuron (Leggere et al., 2016). Netrin proteins are guidance protein
that are produced in the ventral floor plate and that promote commissural neuron
outgrowth by attracting it towards the ventral plate (Stoeckli, 2018; Duman-Scheel,
2009). Although Nova2 loss of function leads to agenesis of the corpus callosum (ACC),
Dcc-long alone could not rescue the ACC defect in Nova2-/- mice (Saito et al., 2016).
Dcc-long, however, was able to restore the normal spinal commissural neuron
development in Nova1/2 dKO mice (Leggere et al., 2016).
The splicing regulatory role of NOVA2 is also critical for brain development,
neurite outgrowth, and neuronal cell differentiation (Saito et al., 2019; Mattioli et al.,
2020). Loss of function of NOVA2 significantly affects neuronal migration (Yano et al.,
2010) and neurite outgrowth (Mattioli et al., 2020). The de novo frameshift mutations in
Mattioli et al. (2020) also significantly altered neuronal cell differentiation and neurite
outgrowth in vivo.
Nova2 mediates its splicing regulatory effect in different parts of the central
nervous system by discriminately binding to specific neurons and neuronal cell types,
hence regulating differently the same RNA transcripts in different neurons and neuronal
cells (Saito et al., 2019). By using the Nova2 cTag-CLIP method, Saito et al. (2019)
discovered that the binding profiles of Nova2 are significantly different between
inhibitory (GABAergic) and excitatory (glutamatergic) neurons in the developing brain
cortex, and that the AS events in these two neuronal populations are different. This
discriminatory splicing effect of Nova 2 appears to be critical to the proper development
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of hippocampus and neocortex. The discriminatory binding of Nova2 is also evident in
the cerebellum, where Nova2 binds selectively to transcripts in Purkinje cells inhibitory
neurons, with high binding specificity to 3' UTR binding sites on RNA transcripts (Saito
et al., 2019). Loss of this Nova-mediated effect in the Purkinje cells leads to cell-specific
progressive motor discoordination and cerebellar atrophy. Taken together, these findings
suggest a Nova2-specific and discriminatory binding on the same transcript in different
neurons and cell types (Saito et al., 2019).
The mechanism of Nova2 AS regulation appears to be due to its negative
interaction effect with another splicing regulator, PTBP2 (Saito et al., 2019). To this
effect, Saito et al. (2019) found out that Nova2 increases the removal of introns in the
alternatively spliced transcripts, hence blocking the binding of PTBP2 to the intronic
regions of the mRNA transcript.
Nova2 is also highly expressed in endothelial cells during angiogenesis and its AS
role is critical for vascular lumen formation and endothelial cell polarity (Giampietro et
al., 2015). Loss of Nova2 disrupts these processes and leads to altered endothelial cells
polarity and impaired vascular lumen formation (Giampietro et al., 2015). Nova2 splicing
regulatory role in these cells involves the AS of transcripts of key effectors of endothelial
cell polarity, including: Par3 (exon 7 inclusion), Magi1 (exon 13a inclusion), Rap1GAP
(exon 18a suppression), Dock6 (exon 24 suppression), Dock9 (exon 37a suppression),
DBS (exon 37 inclusion) and Pix-α (exon 17 suppression) (Giampietro et al., 2015).
2.2.4 Dual functional role of Nova1 and Nova2
Nova1 appears to play a cooperative function with Nova2 (Ruggiu et al., 2009;
Leggere et al., 2016; Saito et al., 2016). Nova1 and Nova2 proteins appeared to play a
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dual role in motor nerve function through: (1) NMJ formation, through the AChR
clustering function of the Nova-spliced, Z exon-containing (Z+) Agrin proteins and (2)
the motor nerve functioning, through the motor firing functional role of unidentified
Nova targets at the proximal motor nerve region (Ruggiu et al., 2009). Nova1/2 double
knock out (dKO) mice in Ruggiu et al. (2009) were paralyzed due to defective motor
function both at the motor nerve and NMJ. Nova1/2 loss of function also disrupts dorsal
interneuron development and completely affects auditory efferent innervation (Saito et
al., 2016).
During the spinal commissural neuron development, Nova 1/2 dKO mice display
defects in the netrin-dependent axon outgrowth process due to disruption of the AS of
Dcc (deleted in colorectal carcinoma) long isoform (Leggere et al., 2016). Dcc is a
netrin-specific receptor on the axon growth cone (Stoeckli 2018; Duman-Scheel 2009).
The mechanism of the cooperative action of both Nova1 and Nova2 in the brain and
spinal cord is not clear. These two Nova homologues are expressed in a reciprocal
manner in central nervous system and their synergistic effect on neuronal development is
still unelucidated.
Both Nova1 and Nova2 are highly expressed in white adipocytes and they both
regulate a wide array of AS events associated with diet-induced obesity and adipose
tissue thermogenesis, including exon inclusion (768 exons), mutually exclusive exon
repression (128 exons), intron activation (99 introns), 64 alternative 5’ splice sites (64
sites), and 110 alternative 3’ splice (Vernia et al., 2016). The splicing regulation of both
Nova1 and Nova2 is essential for metabolism and energy expenditure of high fiber diet
and is thus a promoter of diet induced obesity (Vernia et al., 2016).
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2.2.5 Nova/Agrin function is critical for NMJ formation, development, and
maintenance
The AGRN gene encodes a large protein named AGRIN comprised of around
2000 amino acids (~200 kDa) (Nitkin et al., 1987), and has been cloned from several
vertebrates including rat (Rupp et al., 1991), chick (Tsim et al., 1992; Denzer et al.,
1995) marine ray (Torpedo californica) (Smith et al., 1992), man (Groffen et al., 1998),
and the invertebrate C. elegans (Hurs et al., 2007). Agrin is one of the first proteins found
to be involved in the formation and development of the NMJ (Burden et al., 2018). NMJ
formation is a multistep process requiring sophisticated interaction between
presynaptically-secreted motoneuron-derived Agrin and LRP4 (low-density lipoprotein
receptor-related protein 4) that activates the receptor tyrosine kinase MuSK (musclespecific kinase) on postsynaptic membrane. Consequently, AChRs aggregate into clusters
at the postsynaptic membrane, an essential prerequisite for fast, robust, and reliable
synaptic transmission (Zhang et al., 2008; Zong et al., 2012; Zong and Rongsheng,
2013). A reduced number of AChRs at the NMJ leads to defective synaptic transmission
and is responsible for variety of CMS.
Agrin undergoes AS at three different sites termed X, Y, and Z sites with inserts
of 3/12, 4, and 8/11/19 amino acids (AAs), respectively (Gautam et al., 1996), making
Agrin a unique model gene to study regulatory mechanism of AS. In mammals, there are
two alternative exons at the Z site, termed Z8 and Z11 as they encode for 8 and 11 amino
acid (AA) peptides, respectively (Gautam et al., 1996). Expression of Z exons is neuronspecific, thus generating Z+ Agrin in neurons, while Z- Agrin is expressed ubiquitously
(Gautam et al., 1996). It has been shown that Z8 Agrin is sufficient to induce AChRs
clusters and is ~1,000-fold more active than Z- Agrin (Gautam et al., 1996). Agrin null
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mice and motoneuron-specific Z exons KO (knock out) mice (AgrinZ-/Z-) are unable to
form NMJs and die at birth from diaphragmatic paralysis (Buckanovich et al., 1993;
Darnell et al., 2003). AS at Z site of Agrin is regulated by Nova (Ruggiu et al., 2009).
Nova harbors 3 KH-type RNA-binding domains and each KH domain has a GXXG motif
and a variable loop (Buckanovich et al., 1993; Jensen et al., 2000; Hollingworth et al.,
2012). In vitro RNA selection (Buckanovich et al., 1993; Jensen et al., 2000; Licatalosi et
al., 2008) along with X-ray crystallography (Lewis et al., 2000) revealed that Nova
specifically recognizes YCAYs clusters on pre-mRNA transcripts. Moreover, three
distinct methodologies, including CLIP (Licatalosi et al., 2008; Ule et al., 2003) splicing
microarrays (Ule et al., 2005), and bioinformatics analysis (Ule et al., 2006) have led to
the identification of numerous targets of Nova at the neuronal synapses and also showed
that Nova binds to YCAY clusters on pre-mRNA in vivo. An in silico study predicted that
binding of Nova to intronic YCAY clusters promotes inclusion of alternative exons (Ule
et al., 2006). In mammals, Nova has two members in its gene family: Nova1 and Nova2.
Nova dKO mice show dramatic reduction in the inclusion of Z exon of Agrin, and the
animal dies immediately after birth from diaphragmatic paralysis (Ruggiu et al., 2009).
2.2.6 Ciona robusta as an animal model to study RNA-regulatory networks at the
NMJ
Phylogenetically, tunicates (or sea squirts) are invertebrate chordates and are the
closest living relatives to vertebrates (Delsuc et al., 2006). The invertebrate C. robusta is
a suitable model organism with many experimental advantages, i.e. small size, rapid
development, easy maintenance, cellular simplicity, streamlined and compact genome
that has not undergone the duplications seen in vertebrates. Ciona is particularly
amenable to molecular perturbation and imaging, and its connectome (Bentley et al.,
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2016) is only the second one to be completely mapped after that of the nematode
Caenorhabditis elegans (Hrus et al., 2007), which makes it a powerful tool for genetic
analysis. Adult sea squirts are simple, sessile, filter-feeding animals and their freeswimming tadpole-like larvae are composed of only ~2,600 cells and display a simplified
body plan that is chordate in a mode of development (Satoh, 1994; Satoh et al., 1995).
The tunicate Ciona has emerged as a powerful model for studying chordate-specific
developmental mechanisms and evolutionary biology (Pennisi, 2002). The dorsallylocated larval central nervous system of Ciona robusta comprises only 177 neurons
distributed rostrocaudally in a brain vesicle, a motor ganglion, and a nerve cord (Ryan et
al., 2016). To investigate the regulatory mechanism of AS of neural Agrin by Nova, we
have cloned cDNA of putative Agrin and Nova genes from the tunicate Ciona robusta.
We used Ciona for the first time to study regulatory mechanism of AS of neural Agrin.
The findings are discussed in the following sections.
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2.3 MATERIALS AND METHODS
2.3.1 Animal model and mammalian cell
The tunicate, Ciona robusta, a marine invertebrate was used as an animal model
in our study. The tissue sample of Ciona was collected to clone full length Agrin and
Nova. Human HEK293T cells (ATCC) were used to transfect/co-transfect all the
constructs generated in this study.
2.3.2 Cloning procedures
A total of 33 CiAgrin minigene constructs (WT and mutants) and 17 CiNova
constructs (WT and mutants) were prepared to investigate the regulatory mechanism of
Nova/Agrin splicing and to discover the specific RNA-binding domain(s). Moreover, 16
mouse Nova (WT and mutants) were prepared to investigate splicing of mouse Agrin
minigene mAgrin_31-34-3x-Flag (Saito et al., 2016) (a gift of Dr. Robert B. Darnell from
Rockefeller University). A mouse Dcc minigene (Leggere et al., 2016) (a gift of Dr. Zhe
Chen from University of Colorado, Boulder) was also used for verification of our splicing
assay in our lab. To investigate the disease pathology of epileptic encephalopathy in a
proband, 9 SLC25A10 minigene constructs, including WT and mutants, were constructed.
Ciona minigenes and SLC25A10 minigenes were cloned in pCi-neo vector (Promega).
Mouse Snap25 minigene was cloned in the exon trapping vector pSPL3 (Nisson et al.,
1994; Tompson et al., 2017). Mouse Dcc minigene, is cloned in pDEST26 (Invitrogen).
cDNA constructs of Ciona and mouse Nova were cloned in pEGFP-C1 vector
(Clontech). All these vectors contain a CMV promoter, including mAgrin_31-34-3x-Flag
(Saito et al., 2016). Moreover, cDNA constructs of mouse Nova1, Nova2, Rbfox1, Ptbp2,
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and Mbln2 were cloned in pCAGGS-3x-Flag vector (a gift from Dr. Chaolin Zhang from
Columbia University).
2.3.3 Proof-reading PCR
A mixture of 5 X buffer (10 μL); 10 mM dNTPs (1 μlL; 10 μM forward primer
(2.5 μL); 10 μM reverse primer (2.5 μL); template genomic DNA from Ciona robusta (10
ng); Q5 Hot Start High-Fidelity DNA Polymerase 2,000 U/ ml (New England BioLabs)
(0.3 μlL was prepared in total volume of 50 μL (diluted in sterile nuclease-free H2O) in a
PCR tube. Some of the reactions were supported by adding 10 μl of 5 M Betaine Solution
(Sigma), for a final concentration of 1 M Betaine. PCR reactions were performed in a
T100 thermal cycler (Bio-Rad) with initial denaturation for 5 minutes at 98 °C; variable
number of cycles, followed by 2 minutes of final extension at 72 °C and a hold at 4 °C.
The annealing temperature for each primer pair was calculated using New England
BioLabs Tm calculator version 1.13.0 (http://tmcalculator.neb.com/#!/ as of April 2021).
2.3.4 Site-Directed Mutagenesis
Point mutations (YCAY to YAAY) in Agrin, and deletion mutations in Nova and
its KH domains (GXXG to GDDG) were introduced by Q5 Hot Start DNA Polymerase
(Q5 Site-Directed Mutagenesis Kit, New England Biolabs) according to the
manufacturer. The mutants were cloned into appropriate vectors and were confirmed by
DNA sequencing.
2.3.5 Gel extraction
The PCR product was then purified with a QIAquick Gel Extraction Kit (Qiagen)
according to manufacturer. The DNA fragment was excised from the agarose gel (made
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in TAE buffer) with a scalpel. The gel piece was weighed in an Eppendorf tube. 3
volumes of Buffer QG were added to 1 volume gel. This was followed by an incubation
at 50° C for 10 minutes until the gel slice was completely dissolved (vortexing the tube
every 2-3 minutes). 1 volume of Isopropanol (BDH) was added to the mixture and
vortexed properly. The mixture was then loaded into the QIAquick spin column (DNA
was bound to the membrane of the column) that was attached to a vacuum manifold. The
column was washed two times with 750 μL of Buffer PE in the vacuum manifold. Then
the column was placed in the provided 2 mL collection tube and centrifuged for 1 minute
at 14,500 rpm in order to remove residual wash buffer. The QIAquick spin column was
then placed into a sterile 1.5 mL Eppendorf tube and DNA was eluted with the addition
of 50 μL Buffer EB to the center of the QIAquick membrane, letting the column stand for
2 minutes and centrifuging for 2 minutes at 14,500 rpm. Purified PCR products were
stored at -20° C.
2.3.6 Vector and insert preparation
The mammalian expression vectors (pCi-neo and pEGFP-C1) and the purified
Q5® Hot Start High-Fidelity DNA Polymerase products (i.e. Ciona Agrin and Ciona
Nova) were digested with the appropriate restriction enzymes (New England BioLabs)
according to the manufacturer. Both vector and PCR product digestion mixtures were
prepared with: 10X CutSmart Buffer (10 μL), the enzyme pair used for cloning (3 μL
each) in a final volume of 100 L. 2 μg of vector and the whole purified PCR product
were digested in a total reaction volume of 100 μL (diluted in sterile ddH2O) in separate
tubes. The mixtures were incubated O/N at 37° C. 1 μL of each enzyme was added and
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the mixtures were incubated another hour at 37° C. This was followed by a phenol
chloroform extraction.
2.3.7 Vector dephosphorylation
In order to prevent self-ligation, the 5' phosphate groups rewe removed from the
digested vector prior to ligation. A mixture of the whole amount of digested plasmid (20
μL); CutSmart buffer (3 μL); Shrimp Alkaline Phosphatase (rSAP) (New England
BioLabs) (1.5 μL); 5.5 μL sterile H2O was prepared in an Eppendorf tube. The mix was
then incubated for 30 minutes at 37° C, followed by an incubation for 5 minutes at 65° C
to inactivate the enzyme according to the manufacturer. This was followed by a phenol
chloroform extraction.
2.3.8 Phenol Chloroform extraction and DNA/RNA precipitation
The Phenol Chloroform extraction was performed by adding 180 μL
Phenol:Chlorophorm (AMRESCO) to the DNA or RNA + enzymes mixture and H 2O to
360 μl. The resulting mix was vortexed and spun for 5 minutes at 12,000g. The
supernatant was transferred to a new Eppendorf tube. This was followed by addition of 3
M Sodium Acetate (AMRESCO) pH 5.2, (20 μl); GlycoBlue 15 mg/ml (Ambion) (2 μL)
and 2.5 volumes of 100% Ethanol (Fisher Schientific) (500 μL). The mixture was
vortexed and incubated for 30 minutes at - 80° C. It was then spun for 30 minutes at 4° C
at 1,200g. The supernatant was removed, and the pellet was washed with 70% Ethanol
(500 μL). This was followed by a 10-minute centrifugation at 4° C and 12,000g. The
supernatant was removed, and the pellet was dried at 37° C. H2O was added according to
expected concentration, and the nucleic acid concentration was measure using a
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BioSpectrometer spectrophotometer (Eppendorf). Resulting pure DNA was stored at -20°
C. Resulting pure RNA was stored at -80° C.
2.3.9 Ligation of insert and plasmid
Ciona Agrin inserts (and other minigenes) were cloned into the pCI-neo
mammalian expression vector (Promega) (5472 bp) and Ciona Nova (and other splicing
factors) inserts were cloned into pEGFP-C1 vector (Clontech) (4731 bp). The insert
integration was performed using T4 DNA Ligase (New England BioLabs) and an insertto-vector ratio of 3:1. A mix of 50 ng of vector (1 μL); 2 μL 10X Ligation Reaction
Buffer; 1 μL T4 DNA Ligase was prepared in an Eppendorf tube. It was centrifuged
briefly and incubated O/N at 16° C. The mix was then used to transform Escherichia coli
DH5α competent cells.
2.3.10 Transformation of E. coli DH5α cells
Ligation products were transformed into competent E. coli DH5α cells (New
England BioLabs). The competent cells were thawed on ice. About 4 μL of the ligation
mixture was added to 50 μL of competent cells and mixed by flicking the tube 2-3 times.
The mix was then placed on ice for 30 minutes. This was followed by a heat shock at 42°
C for 30 seconds. After this, 950 μL of room temperature SOC media was added, and the
cells were shaken at 250 rpm for 60 minutes at 37° C. The cells were then spread on LB
agar (AMRESCO) plates under antibiotic selection and incubated overnight at 37° C.
2.3.11 Miniprep
Colonies from transformation plates were picked with a toothpick and grown
overnight at 37° C while shaking at 250 rpm in 5 mL LB medium (AMRESCO)
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supplemented with the appropriate antibiotic (AMRESCO). Before the miniprep
procedure, each cell culture was streaked on LB agar plates (AMRESCO) containing the
appropriate antibiotic; plates were incubated overnight at 37° C, and then stored at 4° C.
The bacterial culture was harvested by centrifugation at 8,000 rpm in a standard bench
top microcentrifuge for 2 minutes at room temperature. The supernatant was removed.
All purification steps were carried out in a table-top microcentrifuge at 12,000g with a
GeneJET Plasmid Miniprep Kit (Thermo Scientific). The pellet was completely
resuspended in 250 μL Resuspension Solution and transferred to a microcentrifuge tube.
250 μL Lysis Solution was then added and the tube was inverted 4-6 times until the
solution became viscous and slightly clear. 350 μL Neutralization Solution was added
and the tube was immediately inverted 4-6 times. The mix was centrifuged for 5 minutes
to pellet cell debris and chromosomal DNA. The supernatant was transferred to a
GeneJET spin column placed on a vacuum manifold and vacuum was applied to bind
plasmid DNA to the column membrane. The column was washed with 500 μL of Wash
Solution twice. Then the column was placed in the provided 2 mL collection tube and
centrifuged for 1 minute in order to remove residual Wash Solution. The GeneJET spin
column was then placed into a clean 1.5 mL Eppendorf tube and DNA was eluted with
the addition of 50 μl Elution Buffer to the center of the membrane, incubating for 2
minutes at room temperature and centrifuging for 2 minutes. Purified plasmid DNA was
stored at -20° C.
2.3.12 Test cut
The isolated constructs from the miniprep were digested with the restriction
enzymes (New England BioLabs) used for cloning according to manufacturer. The
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digestion mixture was prepared with: 10X CutSmart Buffer (1 μL); the enzyme pair used
for cloning (0.5 μL each). 200 ng of construct in a total volume of the reaction of 10 μL
(diluted in sterile ddH2O). The mixtures were incubated 30 minutes at 37° C. A following
incubation for 5 minutes at 65° C was done in order to inactivate the enzymes.
2.3.13 Gel electrophoresis
The digested constructs were then run on an agarose gel. The gels were made with
variable percentages of Agarose (AMRESCO) in TBE or TAE buffers. 10X TBE was
prepared by mixing Tris Base (AMRESCO) (60.55 g); Boric Acid (AMRESCO) (30.9 g);
0.5M EDTA pH 8.0 (AMRESCO) (20 mL) and bringing the volume to 1L with ddH 2O.
50X TAE was prepared by mixing Tris Base (AMRESCO) (242 g); Glacial Acetic Acid
(AMRESCO) (57.1 mL); 0.5M EDTA pH 8.0 (AMRESCO) (100 mL) and bringing the
volume to 1L with ddH2O. The buffers were autoclave sterilized. TBE gels were used for
gel extraction. For the visualization of DNA, we used 3x GelRed (Biotium) (33 mL in a
100 mL gel), with exception of the gels used for running digested vectors which we
stained with Ethidium Bromide, 10 mg/ml (AMRESCO) (5 μL in a 100 mL gel).
2.3.14 Sequencing
The plasmids containing the inserts of expected length were Sanger sequenced
and the clones with correct insert were used for maxiprep for future cell line transfection.
All the constructs were confirmed by the sequencing. The sequencing was performed by
Genewiz.
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2.3.15 Maxiprep
The appropriate bacterial cells were picked from the streak plate prepared before
the miniprep procedure. They were grown in 1 mL of LB broth supplemented with the
proper antibiotic for 4 hours and then transferred to a flask containing 200 mL of LB
broth for overnight growth at 37° C while shaking at 250 rpm. 50 % Glycerol stocks were
prepared from the bacterial culture and stored at -80° C (937 μL of sterile 80 % Glycerol
+ 563 μL bacterial culture). The bacterial culture was harvested by centrifugation at
5,000g for 10 minutes at room temperature. The supernatant was removed. All
purification steps were carried out with a maxiprep kit (GeneJET Plasmid maxiprep kit
from Thermo Scientific and Macherey Nagel maxiprep kit from Macherey Nagel) at
room temperature. The bacterial cell pellet was resuspended in 6 mL Resuspension
Solution. 6 mL Lysis Solution was added and mixed gently by inverting the tube 4-6
times until the solution became viscous and slightly clear. This was followed by
incubation for 3 minutes. 6 mL Neutralization Solution was then added and mixed
immediately by inverting the tube 5-8 times. This was followed by addition of 0.8 mL
Endotoxin Binding Reagent and mixing by inverting the tube 5-8 times, followed by
incubation for 5 minutes. 6 mL of 96% ethanol was then added and mixed by inverting
the tube 5-8 times. This was followed by centrifugation at 5,000g for 40 minutes to pellet
cell debris and chromosomal DNA. The supernatant was transferred to a 50 mL tube. 6
mL of 96% ethanol was added and mixed by inverting the tube 5-8 times. The sample
was transferred to the column placed on a vacuum manifold and vacuum was applied to
bind plasmid DNA to the column membrane. The column was washed with 8 mL Wash
Solution I and then twice with 8 mL Wash Solution II. The column was then placed in the
collection tube and centrifuged for 5 minutes at 3,000g in a swinging bucket rotor to
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remove residual Wash Solution. The column was transferred to a fresh collection tube. 1
mL Elution Buffer was added to the center of the purification column membrane. This
was followed by incubation for 2 minutes and centrifugation for 5 minutes at 3,000g to
elute plasmid DNA. The purified plasmid DNA was stored at -20° C.
2.3.16 Transfection procedure for splicing assay
The day before the transfection 0.6 x 106 HEK293T cells were seeded per well in
a 6-well plate (USA Scientific) in DMEM culture medium. On the day of transfection, a
total of 2.5 g DNA of minigene, cDNA construct, and empty vector was used to
transfect each of 6 well plate(s) and 7.5 L of linear polyethylenimine (PEI;
Polysciences), MW 25,000 (1mg/mL) was used in a ratio of 1:3 (DNA : PEI). 0.5 g (=
1x) of minigene DNA was used in each well to test splicing with different amount of
splicing factor (0g = 0x, 0.5g = 1x, and 2.0g = 4x). Empty vector was used to bring
the total amount of DNA to 2.5 g (2.0g = 4x, 1.5g = 3x, and 0g = 0x) per well. The
total volume of the DNA mixture was 200 L (Table 6 and 7). First, the exact amount of
DNA in L was pipetted in 1.5 L Eppendorf tube (Eppendorf) and Opti-MEM media
(Thermo Scientific) was used to bring the volume to 192.5 L. Then the mixture was
vortexed thoroughly. Finally, 7.5 L of PEI was added, vortexed, and centrifuged briefly.
The mixture was then incubated for 15 minutes at room temperature. In the meantime,
medium in the cells was aspirated and 2 mL of fresh DMEM medium was added. After a
15 minutes incubation, 200 L of reaction mixture was added to the cell and the plate
was cross-shaked gently. The plate was then incubated for 48 hours at 37 ° C.
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2.3.17 RNA extraction
RNA from transfected HEK293T cells was extracted 48 hours after transfection
using RiboZol RNA Extraction Reagent (AMRESCO) or IBI Isolate (IBI Scientific)
according to the manufacturer. HEK293T cells were homogenized using pipette tip in
500 L RiboZol and transferred into a 1.5 mL Eppendorf tube and incubated for 10
minutes at room temperature to ensure complete dissociation of the nucleoprotein
complexes. This was followed by addition of 100 µL chloroform and shaking the tube
vigorously for 15 seconds. The sample was then incubated for 3 minutes at room
temperature. This was followed by centrifugation at 12,000x rpm for 15 minutes at 4° C.
After centrifugation 3 phases were visible: a) lower red, phenol-chloroform phase; b)
white interphase; c) colorless, upper, aqueous phase. RNA locates exclusively in the
upper phase and about 80% of this phase were transferred to a new tube without touching
the interphase. RNA was then precipitated by adding 250 L of Isopropanol (BDH) and 2
L of RNA grade glycogen (Thermo Scientific). The samples were incubated for 10
minutes at room temperature and then centrifuged at 12,000x rpm for 10 minutes at 4° C.
After centrifugation a white pellet of RNA was visible at the bottom of the tubes. The
supernatant was removed without disturbing the pellet. The pellet was then washed with
500 L of 70% ethanol prepared with RNase-free water – vortexed and centrifuged at
14,000x rpm for 5 minutes at 4° C. After this the pellet was air-dried for 5 minutes and
re-dissolved in RNase-free water (Thermo Scientific) by passing it several times through
a pipette tip and incubating for 10 minutes at 50° C to completely dissolve. After reading
the concentration of RNA with a spectrophotometer the samples were stored at -80° C.
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2.3.18 DNase I treatment
A total of 5 g of RNA were digested with DNase I in order to remove any
genomic DNA contamination from RNA samples in a 50 L reaction containing 1.5 L
of TurboDNase (Thermo Scientific), 5 L of 10X Buffer, and ddH2O to 50 L. After 30
minutes of incubation at 37 °C another 1.5 L of TurboDNase was added to the mixture
and incubated for another 30 minutes. After a total of one-hour incubation 10 L of
TurboDNAse Inactivation Reagent was added and samples were kept at room
temperature for 5 minutes, and the tubes were flicked every 2 minutes to resuspend the
inactivation reagent. Then the tubes were centrifuged at 10,000 rpm for 90 seconds. An
adequate amount of supernatant was collected for further processing.
2.3.19 Reverse transcription
From total RNA we synthesized cDNA using RevertAid First Strand cDNA
Synthesis Kit (Thermo Scientific). A mix of 250 ng RNA and 1 µL of oligo (dT)18 500
ng/µL was prepared in a total volume of 12 µL (diluted in sterile ddH2O). The mix was
incubated for 5 minutes at 65 °C in a PCR machine. After this, an RT reaction mix was
prepared combining the mixture above with the following ingredients in a total volume of
20 µL: 5X RT Buffer (4 µL); RiboLock RNase Inhibitor 20 U/µl (0.5 µL); 10 mM
dNTPs (2 µL); RevertAid RT 200 U/µl (0.5 µl). This mixture was incubated for 1 hour at
42 °C followed by 5 minutes at 72 °C in a PCR machine. After the incubation, 5 µL of
H2O were added to each tube bringing the volume to a total of 25 µL. Each RT reaction
mix had a concentration of 10 ng of starting RNA/µL. 5 µL from each RT reaction,
equivalent to 50 ng of starting RNA, were used as template for each RT-PCR.
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2.3.20 RT-PCR
A mixture of 10X PCR Buffer (5 µL); dNTPs 10 mM (1 µL); forward and reverse
primers each 10 M (1 µL); 5 U/µL HotStarTaq Plus DNA polymerase (Qiagen) (0.4 µL)
or 5 U/µL Dream Taq Hot Start DNA polymerase (Thermo Scientific) (0.4 µL) and RT
reaction (5 µL) in a total volume of 50 µL (diluted in sterile ddH2O) was prepared in a
PCR tube. The PCR reaction was performed with initial denaturation for 5 minutes at 95
°C; variable number of cycles of: denaturation for 30 seconds at 94° C, annealing for 30
seconds at 60°C and elongation for 30 seconds at 72 °C. This was followed by a final
extension of 7 minutes at 72 °C and a hold at 12 °C.
2.3.21 Western Blotting
The cDNA constructs all the pEGFP-Nova (WT and mutants) were co-transfected
with Agrin minigenes into HEK293 cells. After 48 hours cells were collected and
resuspended in lysis buffer: 0.5% deoxycholic acid sodium salt (Fisher), 0.1% SDS
(AMRESCO), 0.5% NP-40 (Calbiochem), 1x PBS and 50% glycerol (AMRESCO)) with
protease inhibitor cocktail (AMRESCO). The lysate was left on ice for 20’. After
sonication at 50% amplitude (Fisher Scientific Sonic Dismembrator Ultrasonic Processor
FB120, 120 W 20 kHz), the lysate was subjected to centrifugation at 14,000 rpm at 4° C
for 15 minutes and the supernatant collected in a fresh tube. Total protein amounts were
calculated using a standard Bradford assay and 10 g of protein extract from each sample
were loaded on a 8% SDS-polyacrylamide gel. Proteins were then transferred from gel
onto PVDF membrane (Millipore, Immobilon-FL) and blocked in Odyssey blocking
buffer (TBS, Li-cor). Membranes were blotted with mouse monoclonal anti-GFP
antibody (Santa Cruz biotech, sc-9996, 1:1000 dilution) and then donkey anti-mouse
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IRDye 800CW secondary antibody (Li-cor, 926-32212, 1:5000 dilution). The signal was
detected using the Odyssey CLx imaging system (Li-cor).
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2.4 RESULTS
2.4.1 Agrin’s Z exons and Nova are conserved in Ciona robusta
To dissect the regulatory mechanism of Agrin splicing by Nova, we cloned fulllength Agrin and Nova cDNAs from hatched larvae at 22.5 hours post fertilization (hpf)
at 20° C and brain from adult Ciona robusta (Fig. 1A, B). Ciona Agrin (CiAgrin) and
Ciona Nova (CiNova) cDNAs are ~8 kb and ~2 kb long, respectively. The Z exons at Z
site of CiAgrin are 18 and 15 bases long and code for 6 and 5 amino acids, respectively.
Therefore, we termed the Z exons from Ciona Agrin Z6 and Z5, respectively. By direct
cloning and sequencing of RT-PCR product, we detected all the different isoforms of Z+
Agrin from larvae at 22.5 hpf and from adult brain (Fig. 1C). Interestingly, robust
expression of Z5 and Z6 splice isoforms was detected in brain tissues while Z11 appears
to be the predominant form in larvae. To investigate the molecular mechanism regulating
AS of the Z exons of CiAgrin, we generated a minigene construct spanning the genomic
region of Ciona Agrin encompassing the Z exons and flanking introns and including the
upstream and downstream constitutive exons (exon 40 and 41; Fig. 2A). This genomic
region was amplified by PCR and cloned into the mammalian expression vector pCi-neo.
We cloned 3 isoforms of CiNova form Ciona and we named them CiNova_MMM,
CiNova_MLN, and CiNova_MEY respectively based on the first 3 AA at the N-terminus
(Fig. 1D). These 3 isoforms are the product of AS where two different first exons can be
used: Inclusion of a distal first exon, termed exon 1a, gives rise to CiNova_MMM, while
inclusion of a proximal first exon, termed exon 1b, gives rise to CiNova_MLN and
CiNova_MEY. Of these 3 isoforms, only CiNova_MMM has a nuclear localization
signal (NLS) present in first exon 1a. CiNova_MLN and CiNova_MEY, on the other
hand, include an alternative first exon 1b that does not include an NLS. Therefore, in
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Ciona, Nova undergoes AS at the first exon to generate two isoforms: one that contains
an NLS, and a second one that does not. Compared to CiNova_MLN, CiNova_MEY uses
a downstream first codon and therefore lacks the first 4 AA at its N-terminus. The 3 fulllength Ciona Nova cDNAs were cloned into the pEGFP-C1 mammalian expression
vector in order to generate Nova constructs tagged with EGFP in-frame at their Ntermini.
2.4.2 Nova promotes inclusion of Agrin’s Z exons in a dose-dependent manner and
Z exons splicing is species specific
To investigate the mechanism regulating AS of the Z exons of CiAgrin, we
generated a minigene construct (Fig. 2A) spanning the genomic region of Ciona Agrin
encompassing the Z exons and flanking introns and including the upstream and
downstream constitutive exons (exon 40 and 41). This genomic region was amplified by
PCR and cloned into the mammalian expression vector pCi-neo. To perform in vitro
minigene splicing assays, we co-transfected constant amounts of our Ciona Agrin
minigene construct with increasing amounts of EGFP-CiNova in HEK293T cells. Total
RNA was extracted, quantified, normalized and subjected to AS analysis by semiquantitative RT-PCR. Using this splicing assay, we discovered that all 3 CiNova
constructs promote inclusion of CiAgrin’s Z exons in a dose-dependent manner. This
means that all Ciona isoforms of Nova are able to splice independently of their Nterminus; that is, independently of whether the N-terminus includes the canonical NLS or
not. In details, in this in vitro splicing assay we were able to detect two Z isoforms of Z+
Agrin: Z5 and Z11 (Z6+Z5), but not Z6 (Fig. 2D). To confirm the expression of the
CiNova proteins tagged with EGFP at the N-terminus, we co-transfected all 3 EGFPCiNova constructs with our CiAgrin minigene in HEK293T cells and analyzed EGFP39

Nova protein expression by western blotting. All Nova proteins were robustly expressed
in a dose-dependent manner (Fig. 2E). For simplicity, all further splicing assays of
CiAgrin (WT and mutants) were performed using CiNova_MLN.
In mammals, there are two different NOVA genes which encode for two highly
homologous proteins, NOVA1 and NOVA2. Ruggiu et al. (2009) reported that mouse
Nova (mNova1 and mNova2) regulates AS of mouse Agrin and mNova dKO mice
significantly abolish inclusion of Z exons and the dKO mice die immediately after birth.
We generated two cDNA constructs of mouse Nova into the pEGFP-C1 mammalian
expression vector to further investigate the splicing of Z exons of mouse Agrin in our in
vitro splicing assay system. We used a mouse Agrin minigene spanning the genomic
region of Agrin encompassing the Z exons (32 and 33) and flanking introns and including
the upstream and downstream constitutive exons (exon 31 and 34) used in previous
studies (Fig. 2B). Co-transfection was carried out in HEK293T cells with constant
amounts of mouse Agrin minigene and increasing amounts of EGFP-mNova1 or mNova2
and we found that both mNova1 and mNova2 promote inclusion of Z exons in a dosedependent manner. In our minigene splicing assay we were able to detect only the Z8
isoform of Z+ Agrin (Fig. 2F).
RBFOX1 (also known as A2BP1 or FOX1) is a neuron-specific RNA-binding
protein that exerts both positive and negative regulatory effects on AS (Underwood et al.,
2005). RBFOX1 has been implicated in numerous neurodevelopmental and
neuropsychiatric disorders including autism spectrum disorder, mental retardation and
epilepsy (Ballah et al., 2004; Martin et al., 2007; Sebta et al., 2007; Wang et al., 2009;
Voineagu et al., 2011; Wintle et al. 2011), attention deficit hyperactivity disorder (Elia et
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al., 2010), bipolar disorder, schizoaffective disorder and schizophrenia (Xu et al., 2008;
Le‐Niculescu et al., 2009; Hamshere et al., 2009). Two other important alternative
splicing regulators in brain development Ptbp2 (Licatalosi et al., 2012) and Mbln2
(Charizanis et al., 2012) were also used to investigate any potential alternative splicing
regulation of mouse Agrin and Snap25 minigenes. To explore if mouse Rbfox1 regulates
AS of the Z exons of mouse Agrin, we co-transfected Rbfox1 with the mouse Agrin
minigene in HEK293T cells and discovered that Rbfox1 regulates the splicing of Agrin
by promoting inclusion of the Z exons in a dose-dependent manner as well (Fig. 2G). To
our knowledge there is no known cis-acting element for Rbfox1 in mouse Agrin and its
splicing regulation has never been reported by Rbfox1. Moreover, we have not observed
any splicing regulation when mouse Agrin minigene was tested against splicing factors
Ptbp2 and Mbnl2 (data not shown), suggesting that the regulation of Agrin’s AS by
Rbfox is specific. Leggere et al., 2016 reported that Nova regulates the AS of Dcc premRNA. We carried out splicing assays in HEK293T cells by co-transfecting mouse Nova
with a Dcc minigene containing the genomic DNA between exons 16 and 17 and verified
that we could replicate the results by Leggere et al., 2016 (Fig. 2H, I).
2.4.3 Expression of Agrin’s Z isoforms is developmentally regulated
We collected tissue samples from different developmental stages of Ciona,
extracted total RNA, and investigated the expression of Agrin and Nova by semiquantitative RT-PCR. In this analysis we also included unfertilized eggs, and adult brain
and heart tissue. We found that, while total Agrin and Nova are robustly expressed
throughout development (Fig. 3, first panel and third panel), Agrin’s Z exons start to be
included at 10 hpf (Fig. 3, first panel). Interestingly, our RT-PCR data indicate that Z11
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is the most abundant Z+ Agrin isoform, peaking in hatched larvae at 22.5 hpf during
development, while the smaller Z5 isoform appears to be the predominant one in adult
brain (Fig. 3, first panel). We also observed weak expression of Nova and Z+ Agrin in
heart muscle of Ciona. Interestingly, total Agrin is also robustly expressed in unfertilized
eggs, suggesting that Agrin is maternally inherited in Ciona, and it may play an important
role during early stages of larval development. The expression of Actin was monitored as
experimental (housekeeping) control (Fig. 3, last panel).
2.4.4 Nova requires its first two KH domains to splice Agrin’s Z exons while KH3 is
dispensable
KH (hnRNP K-homology, ~70 AA long) domains are evolutionarily conserved
RNA-binding domains that are present in both eukaryotes and prokaryotes (Musco et al.,
1996; Siomi et al., 1993; Grishin et al., 2001) and are found in a wide range of nucleic
acid binding proteins, including Nova that harbors 3 KH domains and is exclusively
expressed in the central nervous system and in certain tumors (Zhang et al., 2016;
Buckanovich et al., 1993; Darnell et al., 2003). KH domain-harboring proteins play key
roles in many cellular processes, such as translation, AS of pre-mRNA, and mRNA
localization (Buckanovich et al., 1993; Darnell et al., 2003; Siomi et al., 1993) and loss
of function of KH domains is associated with several diseases, including paraneoplastic
syndromes and some cancers (Valverde et al., 2008). Previous work showed that a
missense mutation in the KH domain of FMRP1, the fragile X mental retardation gene,
impairs RNA binding and causes severe mental retardation in humans (Siomi et al.,
1994). KH domains have a conserved GXXG motif and a variable loop (Buckanovich et
al., 1997; Jensen et al., 2000; Hollingworth et al., 2012) and it has been shown that
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mutating the conserved GXXG motif to GDDG abolishes RNA-protein interactions while
keeping the protein structure intact (Hollingworth et al., 2012).
To determine which KH domain or domains of CiNova is/are required for splicing
of Z exons, we generated KH GDDG mutants in all possible combinations including
single (KH1, KH2, KH3), double (KH1/KH2, KH2/KH3, KH1/KH3), and triple
(KH1/KH2/KH3). To this end, we co-transfected HEK293T cells with a constant amount
(1x) of CiAgrin minigene with varying amounts (0x, 1x, 4x) of WT and all the GDDG
mutants of CiNova. Total RNA was extracted, quantified, and subjected to RT-PCR
analysis to determine the inclusion of Agrin’s Z exons by WT and GDDG CiNova
mutants. We observed that WT CiNova promotes inclusion of Z exons in a dosedependent manner, while CiNova KH1 and KH2 GDDG mutations abolish splicing (Fig.
4B). However, mutation of the third KH domain has no negative effect on splicing. RTPCR analysis of co-transfection experiments including KH GDDG double and triple
mutants further suggests that CiNova requires both KH1 and KH2 domains for promoting
Z exons inclusion, while KH3 is dispensable (Fig. 4B). Since CiNova_MMM and
CiNova_MLN have different N-terminal, we therefore generated all the combinations of
KH GDDG mutants for CiNova_MMM and co-transfected them with our CiAgrin
minigene in HEK293T cells. Despite their different N-termini, in our splicing assays we
were unable to detect any differences in splicing activity between CiNova_MLN and
CiNova_MMM GDDG mutants (Fig. 6A, B). To investigate KH domain requirement by
mouse Nova, we also generated all the combinations of KH GDDG mutants of both
mouse Nova1 and Nova2 and co-transfected them with our mouse Agrin minigene in
HEK293T cells. We found that only KH3 GDDG mutant of Nova2 abolishes splicing of
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Z exons of mouse Agrin (Fig. 7C), while none of the individual KH mutant of Nova1
abolishes splicing (Fig. 7A). However, double and triple KH GDDG mutants of both
Nova1 and Nova2 completely abolish splicing of Z exons of mouse Agrin (Fig. 7B, D).
2.4.5 Novel function of N/C-terminals and KH3 domain of Nova
To investigate possible novel function of N and C-terminals and KH3 domain, we
generated 7 deletion mutants of CiNova by deleting N and C-terminals, KH3 domain and
various combinations of them. We discovered that deleting either N- or C-terminals or
both of them together completely abolishes splicing of Z exons of CiAgrin even though
both KH1 and KH2 domains are intact (Fig. 5A,6C). Consistent with our data indicating
that KH3 is dispensable for splicing, KH3 deletion mutant has no effect on splicing, as
expected. Interestingly, splicing of Z exons was rescued when deletion of either N- and
C-terminus or both together was coupled with the deletion of KH3 domain, a finding that
suggests a complex regulatory mechanism of splicing between different intramolecular
CiNova domains (Fig. 5B, 6D).
2.4.6 A bipartite intronic splicing enhancer mediates Nova-dependent inclusion of
Agrin’s Z exons
Nova targets are enriched in YCAY clusters as Nova specifically recognizes
YCAY sequences on pre-mRNA (Jensen et al., 2000; Ule et al., 2003; Ule et al., 2005;
Ule et al., 2006). YCAY-rich sequences on Nova targets can be exonic or intronic and are
conserved between mouse and human (Ule et al., 2006). The position of the YCAY
cluster and Nova’s binding to specific cluster(s) determines splicing outcome (Ule et al.,
2006). Previous work has shown that Nova promotes inclusion of alternative exons when
it binds to intronic YCAY clusters downstream of alternative exons, but binding to a
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cluster located on the alternative exon or upstream of it, on the other hand, doesn’t
promote inclusion but skipping (Ule et al., 2006). Mutating the targets of Nova from
YCAY to YAAY has been shown to abolish both Nova binding (Buckanovich et al.,
1997) and splicing (Leggre et al., 2016). In CiAgrin intronic YCAY sequences are
exclusively concentrated in the intron downstream of exon Z5 (18 YCAY sequences in
intron 40) and only 5 YCAY sequences are present on flanking constitutive exons: one in
exon 40 and 4 in exon 41 (Fig. 8A).
To dissect the cis-regulatory YCAY elements of CiAgrin that may mediate Novadependent inclusion of the Z exons, we generated 32 mutant minigenes of CiAgrin by
mutating its 23 YCAY sequences to YAAY in different combinations (Fig. 8E). To this
end, co-transfection of constant amounts (1x) of CiAgrin minigene (WT and YAAY
mutants) with varying amounts (0x, 1x, 4x) of CiNova in HEK293T cells was performed.
Total RNA was extracted, quantified, and subjected to semi-quantitative RT-PCR
analysis to monitor the inclusion of Agrin’s Z exons by CiNova. Our results suggest that
we have identified two Nova-dependent intronic splicing enhancers (NISE) elements,
termed NISE1 and NISE2, in intron 40 (Fig. 8E). NISE1 contains the first 6 YCAY
sequences while NISE2 covers YCAY11 to YCAY14 (Fig. 8A, E). Exonic YCAY
sequences, on the other hand, are not required for splicing at the Z site of CiAgrin (Fig.
8B). We noticed that in CiAgrin the average nt distance between the intronic YCAY
repeats is 32. Interestingly, the average nt distance in the NISE elements is reduced to 10
nt and 22 nt in NISE1 and NISE2, respectively. However, our findings suggest that the
spacing between single YCAY sequences does not appear to be critical for splicing (Fig.
8F). For example, YCAY 6 and 7, the closest YCAYs, are only 2 nt apart and double
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mutant YAAY 6-7 cannot abolish splicing. Conversely, YCAY 12 and 13 are also 2 nt
apart but double mutant YAAY 12-13 is unable to splice. At the other end of the
spectrum, YCAY 13 and 14 are 56 nt apart, and double mutant YAAY 13-14 is unable to
splice, while ICAY 17 and 18 are 111 nt apart but double mutant YAAY 17-18 is still
able to splice.
2.4.7 Agrin’s Z exons splicing is species specific
To determine species specificity of Agrin’s Z exons splicing, we co-transfected
CiAgrin minigene with individual cDNA constructs of Nova from either mouse or Ciona
in HEK293T cells. Total RNA was extracted and subjected to semi-quantitative RT-PCR
analysis. The contemporary experiment was also performed where HEK293T cells were
co-transfected with mouse Agrin minigene and Nova from either mouse or Ciona and
subjected to semi-quantitative RT-PCR analysis after total RNA extraction. We observed
that the Z exons of Agrin are spliced only by its species-specific Nova: Nova from mouse
cannot splice CiAgrin minigene and mouse Agrin minigene is not spliced by mouse Nova
(Fig. 9A, B).
2.4.8 Exons 5a and 5b of Snap25 are regulated by mouse Nova1/2, Rbfox1, and
Ptbp2 but not Mbnl2
SNAP25 plays a crucial role in neuroexocytosis by linking synaptic vesicles to the
plasma membrane during regulated neurotransmitter release. Exon 5 of SNAP25 is a
perfect example of exon duplication, a process of proteomic diversification. Exons 5a and
5b are subjected to mutually exclusive AS that results in two splice variants, SNAP25a
and SNAP25b (Letunic et al., 2002). Several mutations affecting SNAP25b isoform have
been reported in patients with neurological illnesses including myasthenia, intellectual
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disability, and cerebral ataxia (Engel et al., 2018; Shen et al., 2014; Fukuda et al., 2018).
Snap25 knockout mice revealed that the Snap25b isoform shows a higher capability in
stabilizing primed vesicles than Snap25a (Sørensen et al., 2003). Transgenic mouse
models have revealed that the splicing ratio of exons 5a and 5b of Snap25 is
developmentally regulated and decreased expression of 5b resulted in developmental
defects, spontaneous seizures, and impaired short-term synaptic plasticity (Johansson et
al., 2008). From iCLIP study Gehman et al., 2011 reported that Rbfox1 has many
(U)GCAUG motifs adjacent to exon 5b suggesting a possible splicing regulation of this
exon by Rbfox1.
To specifically explore the splicing of exon 5a and 5b, a minigene pSP-Snap255a/b containing 2625 nt of genomic region encompassing exon 5a and 5b from the
Snap25 gene (Fig. 11A) was generated and tested in minigene splicing assays with
various splicing factors including Nova1, Nova2, Rbfox1, Ptbp2, and Mbnl2. All 5 of
these splicing factors were cloned in pCAGGS-3x-Flag vector. Since exon 5a and 5b are
identical in size (118 nt), it is not possible to distinguish them by gel electrophoresis after
semi-quantitative RT-PCR. Interestingly, all constructs promote inclusion of either 5a or
5b or maybe both (Fig. 11B). To determine which exon is spliced in in the RNA
transcript, we digested the RT-PCR products with restriction enzymes that are specific
for each alternative exon: an NdeI restriction site present in exon 5a, and an AvrII
restriction site present in exon 5b. Digestion of the RT-PCR products with NdeI generates
two fragments of 194 and 186 bp if isoform 5a is present, while digestion of the RT-PCR
products with AvrII generates two fragments of 211 and 171 bp if isoform 5b is present.
By observing the size of bands on a gel, we confirmed which exon was regulated by
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which splicing factor. Running the digested RT-PCR transcripts on gel, we discovered
that Nova2 and Rbfox1 strongly promote inclusion of exon 5b (Fig. 11D, E), while
Nova1 weakly regulates inclusion of both exons (Fig. 11C). Our observation for Ptbp2
and Mbln2 is slightly different: Ptbp2 promotes only the inclusion of exon 5a (Fig. 11F),
while Mbln2 regulates inclusion of both exons with a preference for the inclusion of exon
5a over 5b (Fig. 11G).
Moreover, to assess the co-regulatory control of splicing at the 5a/b site, we
performed competition experiments where we co-transfected mSnap25 minigene with 2
different splicing factors in HEK293T cells. For example, a varying amount of mRbfox1
(0x, 1x, 3x) was used with a constant amount of mPtbp2 (1x), and vice versa, while the
amount of minigene was always constant (1x). We digested the RT-PCR products with
NdeI and AvrII and overserved splicing regulation on agarose gel. We observed that there
is an antagonistic effect between mRbfox1 and mPtbp2. However, mRbfox1 has strong
preference in recognizing and promoting the inclusion of 5b in the presence of mPtbp2.
We detected dose-dependent inclusion of 5b and skipping of 5a when co-transfection was
carried out with varying amounts of mRbfox1 and constant amount of mPtbp2 (Fig.
12A). On the other hand, co-transfection with varying amounts of mPtbp2 and constant
amount of mRbfox1 resulted in an opposite scenario. In this case, we observed a dosedependent inclusion of 5a and skipping of 5b; interestingly, expression of 5b is much
stronger than 5a (Fig. 12B). We have not observed any effect when mNova1 was cotransfected with varying amounts of mRbfox1 (Fig. 12D). However, we found a dosedependent skipping of 5b when co-transfection with constant mRbfox1 and varying
amount of mNova1 was carried out (Fig. 12C). We have not observed any antagonistic
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relationship between Nova2 and mRbfox1 but a cooperation. In both co-transfection
experiments with constant amounts of mRbfox1 and varying amounts of mNova2, or
constant amounts of mNova2 and varying amount of mRbfox1, we observed strong
inclusion of 5b (Fig. 12E, F).
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2.5 DISCUSSION
In vertebrates Z+ Agrin-mediated clustering of AChRs at the NMJ is critical for
synaptogenesis and muscle stability (Bezakova et al., 2003). However, in invertebrates
(the nematode C. elegans) the expression of Agrin is very weak and transient in
motoneurons in the embryo but not detected in larvae nor in adult stages and its protein
sequence best aligns with Z- Agrin (Hrus et al., 2007), suggesting an Agrin-independent
NMJ formation in nematodes. Moreover, as they could not detect any potential
alternative exons coding for amino acids resembling the conserved inserts in the Z sites
of vertebrates, the authors who cloned and characterized Agrin from C. elegans
concluded that the “Z alternative spice sites are specific to vertebrates”.
A recent study has shown that heparan sulfate -a proteoglycan- is critical for
synaptogenesis in C. elegans (Lázaro-Peña et al., 2018). Contrary to the findings in C.
elegans, we have discovered that the Z alternative splice sites are not specific to
vertebrates but are also present in invertebrates such as Ciona. In mammals, the Z exons
of Agrin -termed Z8 and Z11- encode for 8 and 11 AA peptides (Gesemann et al., 1995),
respectively, but in Ciona the Z exons are even smaller: called Z6 and Z5, they encode
for only 6 and 5 AAs, respectively (Fig. 2A). The presence of Z exons in Ciona suggests
an Agrin/Nova-dependent pathway for NMJ formation, development, and maintenance
that is conserved from tunicates to mammals. Using CRISPR/Cas-9 technology, our
collaborators Dr. Lionel Christiaen at NYU and Dr. Alberto Stolfi at Georgia Tech
generated Agrin KO and Nova KO Ciona animals and found that AChRs clustering at the
NMJ is significantly reduced in KO animals (data not shown). This is consistent with
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findings in Agrin null mice (Gautam et al., 1996; Burgess et al., 1999) as well as in dKO
Nova mice (Ruggiu et al., 2009).
The expression of Z+ Agrin and Nova in Ciona is developmentally regulated. We
observed a strong expression of Z5 and Z11 in the adult brain and 22.5 hpf at 20° C
(swimming larvae) of Ciona, respectively. In mammals, the Z8 isoform is the most
critical one for formation and development of the NMJ, as it is the most potent in
promoting clustering of AChRs (Gesemann et al., 1995; Ruggiu et al., 2009).
Interestingly, we detected robust expression of Z- Agrin in unfertilized eggs (Fig. 3),
suggesting that in tunicates Agrin may be maternally expressed and its mRNA deposited
in the oocyte, and as such it may be critical for early embryonic development before
activation of the zygotic genome. Nova’s expression was consistent throughout the
development but Z+ Agrin first appears at 10 hpf during embryonic development,
suggesting that Nova alone is not sufficient to induce inclusion of Agrin’s Z exons, and
that additional layer(s) of complexity in Z+ Agrin expression that are independent of
Nova are likely at play. At NYU in Dr. Christiaen’s Lab, fluorescent in situ hybridization
(FISH) was performed to validate the expression of Agrin and Nova in Ciona. We
observed a strong expression of Agrin in the brain and the motor ganglion (MG) of Ciona
larvae (data not shown). We also discovered that Nova’s expression is dynamic
throughout development: the expression of Nova is very weak at gastrula stage but is
expressed throughout the body (strongest in the brain and MG) at mid-tailbud stage (data
not shown), including heart precursor cells, suggesting a possible, yet unknown role for
Nova and AS regulation in heart development. Interestingly, a recent paper showed that
Agrin is necessary for heart regeneration following myocardial infraction, although
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whether AS in general and Z exons in particular are involved in this process is not
known. Moreover, we found a dynamic expression of Nova in motor neurons (data not
shown): at 15.5 hpf, Nova’s expression is upregulated in motor neuron (MN) 2 (data not
shown), interestingly, one hour later at 16.5 hpf, Nova’s expression disappears in MN2
but is upregulated in MN1 and interneuron1 (data not shown).
We discovered that in Ciona Nova uses its first two KH RNA-binding domains to
splice Agrin, while KH3 is dispensable. In mammals, Nova uses its KH3 domain for
binding to its target pre-mRNAs (Jensen et al., 2000). Moreover, by generating N- and Cterminal we have discovered a unique function of KH3 domain of CiNova deletion
constructs. Deletion of either N- or C-terminal or both of them together completely
abolishes splicing of CiAgrin’s Z exons. Since the effect on splicing is the same, this
result suggests that the N-terminus and the C-terminus of Nova are part of the same
regulatory domain. Intriguingly, deletion of the KH3 domain rescued the splicing defect
of either the N- or the C-terminus deletions, or both. Our findings uncover previously
unknown complex intramolecular regulatory elements that modulate Nova’s splicing
activity. Our interpretation of our result is as follows: The KH3 domain acts as a negative
regulator of splicing, while the N- and C-terminus are part of a regulatory domain that
negatively regulates the activity of KH3. Deletion of the N- and/or the C-termini
eliminates the domain that suppresses the activity of KH3. As KH3 in turn acts to
suppress the splicing activity of KH1 and KH2, this explains why a version of Nova that
lacks its N- and/or C-terminus can no longer splice Agrin even though the KH1 and KH2
domains of Nova -that is, the two domains that are necessary for Agrin’s splicing- are
still intact. It’s only by deleting the N- and/or C-terminal domains that act as repressors of
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KH3 function that the inhibitory activity of KH3 on KH1 and KH2 is unmasked. We
speculate that this N- and C-terminus domain may act as a regulatory switch that
determines the usage of specific KH domains thus allowing Nova to switch between two
distinct splice modalities: one that is KH1- and KH2-dependent and promotes the splicing
of targets such as Agrin, and a second modality that is KH3-dependent and may regulate
splicing of a different set of targets. The overall picture is likely to be more complex, and
it may require further crystallographic and bioinformatical approaches to understand how
different domains of Nova modulate its splicing activity. Nevertheless, our findings
uncover previously unsuspected layers of regulation of Nova’s splicing activity.
We have determined that CiNova regulates AS by specifically recognizing its
bona fide binding sequence YCAY on CiAgrin’s pre-mRNA. It is known that Nova
promotes exon inclusion by binding to intronic YCAY clusters downstream of alternative
exons; binding to exonic clusters, on the other hand, promote skipping (Ule et al., 2006).
We have discovered two Nova-dependent intronic splicing enhancers (NISE) elements
(termed NISE1 and NISE2) in the intron downstream of Z5. In doing so we also
discovered that at least two, and any two, consecutive YCAY sequences from either
NISE1 or NISE2 are needed to promote Z exons inclusion (Fig. 8), thus contributing to
deciphering the splicing code that mediates Nova-dependent AS regulation. The YCAY
repeats on Nova targets are well conserved in mammals and closely spaced being on
average 28 nt apart (Ule et al., 2006). In Ciona Agrin the average nt distance between the
intronic YCAY repeats is 32 when considering the whole intron, but the average nt
distance is reduced to 10 and 22 nt in NISE1 and NISE2, respectively. However, the
spacing between single YCAY sequences does not appear to be critical for splicing (Fig.
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8F) For example, the closest YCAYs in NICE1, YCAY 6 and 7, are just 2 nt apart and
double mutant YAAY 6-7 is still able to splice correctly. Conversely, YCAYs 12 and 13
in NICE2 are also just 2 nt apart, but double mutant YAAY12-13 is unable to splice. At
the other end of the spectrum, YCAYs 13 and 14 are 56 nt apart, and double mutant
YAAY 13-14 is unable to splice. YCAYs 17 and 18, on the other hand, are 111 nt apart
but double mutant YAAY 17-18 is still able to splice correctly. Based on our findings, we
propose a model for Nova-dependent splicing of neural Agrin where Nova uses its KH1
and KH2 domains to recognize and bind to NISE1 and NISE2 elements on Agrin’s premRNA, respectively or vice versa, and the N- and C-terminus act as a regulatory switch
to negatively regulate the inhibitory function of KH3 domain (Fig. 10).
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2.6 CONCLUSIONS AND FUTURE PERSPECTIVES
In summary, the findings in this chapter provide enough evidence of coevolution
between Nova proteins and the cis-regulatory sequences embedded in the downstream
intron of Z exons of Agrin. We specifically discovered the regulatory mechanism of
Nova-dependent AS of Z exons of Agrin in Ciona robusta. We show that mutation in the
cis- and trans-regulatory elements of Agrin and Nova could potentially dysregulate AS,
which in turn could lead to disorders, particularly neurodegenerative and neuromuscular
diseases. Since Nova/Agrin function is critical for NMJ formation, development, and
maintenance; our studies here could be relevant to shed light to the understanding AS
related diseases including cancer and neurological disorders.
Besides the major accomplishments described in this project, our study has
also raised a number of questions that can potentially lead to new findings. For example,
mSnap25 is differentially spliced at 5a/b site by 5 different splicing factors including
mNova1 and Nova2, mRbfox1, mMbnl2, and mPtbp2. It would be interesting to explore
the molecular mechanism of competition between the splicing factors that we see in our
study. Finding the answer to the question “How and why Rbfox1 regulate splicing of Z
exons of Agrin?” would be another exciting project to investigate.
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2.7 TABLES AND FIGURES
2.7.1 TABLES
Table 1. List of all the forward and reverse primers used to clone Ciona Agrin
constructs used in this study
Construct Name
pCi-CiAgrin-E40-41
pCi-CiAgrin-E40-YAAY
pCi-CiAgrin-E41-YAAY1-2
pCi-CiAgrin-I40-YAAY3-4
pCi-CiAgrin-I40-YAAY1-3
pCi-CiAgrin-I40-YAAY4-7
pCi-CiAgrin-I40-YAAY8-10
pCi-CiAgrin-I40-YAAY11-13
pCi-CiAgrin-I40-YAAY14
pCi-CiAgrin-I40-YAAY15-16
pCi-CiAgrin-I40-YAAY17
pCi-CiAgrin-I40-YAAY18
pCi-CiAgrin-I40-YAAY4-5
pCi-CiAgrin-I40-YAAY5-6
pCi-CiAgrin-I40-YAAY6-7
pCi-CiAgrin-E41-YAAY1-2
pCi-CiAgrin-I40-YAAY2-3
pCi-CiAgrin-I40-YAAY3
pCi-CiAgrin-I40-YAAY12
pCi-CiAgrin-I40-YAAY12-13
pCi-CiAgrin-I40-YAAY4
pCi-CiAgrin-I40-YAAY11
pCi-CiAgrin-I40-YAAY13
pCi-CiAgrin-I40-YAAY3-4
pCi-CiAgrin-I40-YAAY11-12

Forward(F)/Reverse(R) Promers
Ci Agr_E40F1
Ci Agr_E41R1
CiNova E40_YAAY_F
CiNova E40_YAAY_R
CiNova E41_YAAY_1-2_F
CiNova E41_YAAY_1-2_R
CiNova E41_YAAY_3-4_F
CiNova E41_YAAY_3-4_R
CiNova I40_YAAY_1-3_F
CiNova I40_YAAY_1-3_R
CiNova I40_YAAY_4-7_F
CiNova I40_YAAY_4-7_R
CiNova I40_YAAY_8-10_F
CiNova I40_YAAY_8-10_R
CiNova I40_YAAY_11-13_F
CiNova I40_YAAY_11-13_R
CiNova I40_YAAY_14_F
CiNova I40_YAAY_14_R
CiNova I40_YAAY_15-16_F
CiNova I40_YAAY_15-16_R
CiNova I40_YAAY_17_F
CiNova I40_YAAY_17_R
CiNova I40_YAAY_18_F
CiNova I40_YAAY_18_R
CiAgr I40_YAAY_4-5_F
CiAgr I40_YAAY_4-5_R
CiAgr I40_YAAY_5-6_F
CiAgr I40_YAAY_5-6_R
CiAgr I40_YAAY_6-7_F
CiAgr I40_YAAY_6-7_R
CiAgr I40_YAAY_1-2_F
CiAgr I40_YAAY_1-2_R
CiAgr I40_YAAY_2-3_F
CiAgr I40_YAAY_2-3_R2
CiAgr I40_YAAY_3_F
CiAgr I40_YAAY_3_R
CiAgr I40_YAAY_12_F
CiAgr I40_YAAY_12_R
CiAgr I40_YAAY_12-13_F
CiAgr I40_YAAY_12-13_R
CiAgr I40_YAAY_4_F
CiAgr I40_YAAY_4_R
CiAgr I40_YAAY_11_F
CiAgr I40_YAAY_11_R
CiAgr I40_YAAY_13_F
CiAgr I40_YAAY_13_R
CiAgr I40_YAAY_3-4_F
CiAgr I40_YAAY_3-4_R
CiAgr I40_YAAY_11-12_F
CiAgr I40_YAAY_11-12_R

Primer Sequence
CAAGATGAACAAGCGACTGC
GGACCAGAACCAAGGTCAAA
CAAGCGACTGCAATTTATTTGGATG
TTCATCTTGTAGCAAGTCAG
ACTGCTAATGGTGGGCAAAGCGAGGGA
AGACCGTTACGAGCAGTAGTGCGGAAC
CGTCTTAATCTTCGTTTTGACCTTGGTTC
ACCGTCATTAATTGCGAGTGCAATATAATC
TTAACATCGTGCAAATAATTAGTTAGTTTTAGTGTCATTTG
ATTATATGTTGATGCAATTGCAGTTTAACCTAAACATTTCTTAC
ATTAATGTCAATAGGAATGTGCGCACGGGA
TCATTACAAATTACACTAAAACTAACTAATGATTTGCACGATGTTAAATG
TTGTAATTTTGAATTAATGTCAATAGTGCTGTATGAAAAG
ACTAACTGTTAAATATTATCACAAAAAATAGGTCTTTAAAAAATG
ATAATATTAATGCTAACATTGAGAATGCTG
GTTTTAGATTAATTGACCATAAAAAATAAACATAAAG
CTCAAAGCAGTAATAAAAACATTG
CAAGATGTAATATATTTCGAAATC
AAAACCCAACTAACTTATTGTGAGTCCAAC
ACCTTAATTAGTTTTTAGAACCCATCTATATATAAAG
GTAGGCCAAATAATATAACTCTATAAC
TAAGGTATTCTCTGGGGTTG
AATTTCAATATAATTTTTTTTTGTTTAGGC
TTTAGATTTAGGGTGTGTG
TGTAATGAATTCATGTCCATAGG
AATTACACTAAAACTAACTAATGATTTG
ATTAATGTCCATAGGAATGTGCGC
TCATTACAAATGACACTAAAACTAACTAATGATTTG
TGTCAATAGGAATGTGCGCACGGGA
TTAATTCATGACAAATGACACTAAAACTAACTAATGATTTGC
AACATATAATTTAACATCGTGCAAATCATTAG
GATGCAATTGCAGTTTAACCTAAACATTTCTTAC
GTGCAAATAATTAGTTAGTTTTAGTGTCATTTG
GATGTTAAATTATATGTTGATGCAATGGCAG
ATCGTGCAAATAATTAGTTAGTTTTAG
GTTAAATGATATGTTGATGCAATG
ATCTAAAACATAATATTCATGCTAAC
GAATTGACCATAAAAAATAAACATAAAG
TTAATGCTAACATTGAGAATGCTG
TATTATGTTTTAGATGAATTGACCATAAAAAATAAAC
AGTTTTAGTGTAATTTGTCATGAATTC
AACTAATGATTTGCACGATG
ATGGTCAATTAATCTAAAACATCATATTC
AAAAAATAAACATAAAGAGTTTTTTTAAATTC
ACATCATATTAATGCTAACATTGAG
TTTAGATGAATTGACCATAAAAAATAAAC
TTTAGTGTAATTTGTCATGAATTCATGTCC
ACTAACTAATTATTTGCACGATGTTAAATG
AACATAATATTCATGCTAACATTGAGAATG
TTAGATTAATTGACCATAAAAAATAAACATAAAG
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Table 2. List of all the forward and reverse primers used to clone Ciona Nova
constructs used in this study
Construct Name

Forward(F)/Reverse(R) Promers

Ci Nova_MMM_F1_EcoRI
pEGFP-CiNova_MMM
Ci Nova_R1_BamHI
Ci Nova_MEY_F1_EcoRI
pEGFP-CiNova_MEY
Ci Nova_R1_BamHI
Ci Nova_MLN_F1_EcoRI
pEGFP-CiNova_MLN
Ci Nova_R1_BamHI
CiNova KH1_GDDG_F
pEGFP-CiNova_MLN-KH1-GDDG
CiNova KH1_GDDG_R
CiNova KH2_GDDG_F
pEGFP-CiNova_MLN-KH2-GDDG
CiNova KH2_GDDG_R
CiNova KH3_GDDG_F
pEGFP-CiNova_MLN-KH3-GDDG
CiNova KH3_GDDG_R
Ci Nova_MLN_F1_EcoRI
pEGFP-CiNova_MLN-KH1/2-GDDG
CiNova KH2_GDDG_R
Ci Nova_MLN_F1_EcoRI
pEGFP-CiNova_MLN-KH1/3-GDDG
CiNova KH3_GDDG_R
Ci Nova_MLN_F1_EcoRI
pEGFP-CiNova_MLN-KH2/3-GDDG
CiNova KH3_GDDG_R
Ci Nova_MLN_F1_EcoRI
pEGFP-CiNova_MLN-KH1/2/3-GDDG
CiNova KH3_GDDG_R
CiNova ΔN_F
pEGFP-CiNova ΔN
CiNova ΔN_R
CiNova ΔNΔC_F
pEGFP-CiNova ΔNΔC
CiNova ΔNΔC_R
CiNova ΔNΔKH3_F
pEGFP-CiNova ΔNΔKH3
CiNova ΔNΔKH3_R
CiNova ΔNΔKH3ΔC_F
pEGFP-CiNova ΔNΔKH3ΔC
CiNova ΔNΔKH3ΔC_R
CiNova MLN ΔC-ter_F
pEGFP-CiNova MLN ΔC-ter
CiNova MLN ΔC-ter_R
CiNova MLN ΔKH3_F
pEGFP-CiNova MLN ΔKH3
CiNova MLN ΔKH3_R
CiNova MLN ΔKH3ΔC_F
pEGFP-CiNova MLN ΔKH3ΔC
CiNova MLN ΔKH3ΔC_R
CiNova MMM ΔC-ter_F
pEGFP-CiNova MMM ΔC-ter
CiNova MMM ΔC-ter_R
CiNova MLN ΔKH3ΔC_F
pEGFP-CiNova MLN ΔKH3ΔC
CiNova MLN ΔKH3ΔC_R
CiNova MMM ΔKH3ΔC_F
pEGFP-CiNova MMM ΔKH3ΔC
CiNova MMM ΔKH3ΔC_R

Primer Sequence
ACAGTGGAATTCTATGATGATGACGGCCGTAGTACC
ACAGTGGGATCCCTACAGTAACTTAGCCTGCTGTGC
ACAGTGGAATTCTATGGAGTATGAATGCCAGTACAATGC
ACAGTGGGATCCCTACAGTAACTTAGCCTGCTGTGC
ACAGTGGAATTCTATGCTAAATGCAATGGAGTATGAATGCCAGTACAATGC
ACAGTGGGATCCCTACAGTAACTTAGCCTGCTGTGC
GGTGATCGGGGACGACGGTCAGATTATTGTACAACTTCAGAAAGATTCAGGG
GCCCCCGCAGCGTACCCC
GGTAATAGGAGACGACGGCGCAACGATAAAG
AGTCCCGCAGTTGTGTTG
AGTCCTCGGAGACGACGGAAGGACACTG
GCTCCGATCAGGTTTTCG
ACAGTGGAATTCTATGCTAAATGCAATGGAGTATGAATGCCAGTACAATGC
AGTCCCGCAGTTGTGTTG
ACAGTGGAATTCTATGCTAAATGCAATGGAGTATGAATGCCAGTACAATGC
GCTCCGATCAGGTTTTCG
ACAGTGGAATTCTATGCTAAATGCAATGGAGTATGAATGCCAGTACAATGC
GCTCCGATCAGGTTTTCG
ACAGTGGAATTCTATGCTAAATGCAATGGAGTATGAATGCCAGTACAATGC
GCTCCGATCAGGTTTTCG
ACAGTGGAATTCTATGATTCTTAAAGTTCTAATACCGGGGTACGC
ACAGTGGGATCCCTACAGTAACTTAGCCTGCTGTGC
ACAGTGGAATTCTATGATTCTTAAAGTTCTAATACCGGGGTACGC
ACAGTGGATCCCTAGCTTGACTTTTCGATGCTTAGGATACTCA
ACAGTGGAATTCTATGATTCTTAAAGTTCTAATACCGGGGTACGC
ACAGTGGGATCCCTACAGTAACTTAGCCTGCTGTGC
ACAGTGGAATTCTATGATTCTTAAAGTTCTAATACCGGGGTACGC
ACAGTGGATCCCTAGCTTGACTTTTCGATGCTTAGGATACTCA
ACAGTGGAATTCTATGCTAAATGCAATGGAGTATGAATGCCAGTACAATGC
ACAGTGGGATCCCTACGTAATAAGAAACTGCGCAGTCTGT
ACAGTGGAATTCTATGATTCTTAAAGTTCTAATACCGGGGTACGC
ACAGTGGATCCCTAGCTTGACTTTTCGATGCTTAGGATACTCA
ACAGTGGAATTCTATGATTCTTAAAGTTCTAATACCGGGGTACGC
ACAGTGGATCCCTAGCTTGACTTTTCGATGCTTAGGATACTCA
ACAGTGGAATTCTATGATGATGACGGCCGTAGTACC
ACAGTGGGATCCCTACGTAATAAGAAACTGCGCAGTCTGT
ACAGTGGAATTCTATGATGATGACGGCCGTAGTACC
ACAGTGGATCCCTAGCTTGACTTTTCGATGCTTAGGATACTCA
ACAGTGGAATTCTATGATGATGACGGCCGTAGTACC
ACAGTGGATCCCTAGCTTGACTTTTCGATGCTTAGGATACTCA
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Table 3. List of all the forward and reverse primers used to clone mouse Nova and
Agrin constructs used in this study
Construct Name

Forward(F)/Reverse(R) Promers Primer Sequence

mNova1_F_HindIII
mNova1_R_KpnI
mNova2_F_EcoRI
pEGFP-mNova2
mNova2_R_BamHI
mN1 KH1_GDDG_F
pEGFP-mNova1-KH1-GDDG
mN1 KH1_GDDG_R
mN1 KH2_GDDG_F
pEGFP-mNova1-KH2-GDDG
mN1 KH2_GDDG_R
mN1 KH3_GDDG_F
pEGFP-mNova1-KH3-GDDG
mN1 KH3_GDDG_R
mNova1_F_HindIII
pEGFP-mNova1-KH1/2-GDDG
mN1 KH2_GDDG_R
mNova1_F_HindIII
pEGFP-mNova1-KH1/3-GDDG
mN1 KH3_GDDG_R
mNova1_F_HindIII
pEGFP-mNova1-KH2/3-GDDG
mN1 KH3_GDDG_R
mNova1_F_HindIII
pEGFP-mNova1-KH1/2/3-GDDG
mN1 KH3_GDDG_R
mN2 KH1_GDDG_F
pEGFP-mNova2-KH1-GDDG
mN2 KH1_GDDG_R
mN2 KH2_GDDG_F
pEGFP-mNova2-KH2-GDDG
mN2 KH2_GDDG_R
mN2 KH3_GDDG_F
pEGFP-mNova2-KH3-GDDG
mN2 KH3_GDDG_R
mNova2_F_EcoRI
pEGFP-mNova2-KH1/2-GDDG
mN2 KH2_GDDG_R
mNova2_F_EcoRI
pEGFP-mNova2-KH1/3-GDDG
mN2 KH3_GDDG_R
mNova2_F_EcoRI
pEGFP-mNova2-KH2/3-GDDG
mN2 KH3_GDDG_R
mNova2_F_EcoRI
pEGFP-mNova2-KH1/2/3-GDDG
mN2 KH3_GDDG_R
pEGFP-mNova1

ATGCTCAAGCTTCGATGATGGCGGCAGCTCCCATTC
ATGCTCGGTACCTCAACCCACTTTCTGAGGATTGGCA
AGCTTCGAATTCTATGGAGCCCGAGGCCCCGG
ATGGTCGGATCCTCATCCCACTTTCTGTGGGTTTGAAGCCCTCC
TATAATTGGGGACGACGGACAGACAATTGTTCAG
GATCCAGCAGCATAACTAG
GATAATAGGGGACGACGGTGCTACTGTGAAGGC
AGACCTGCTGTGCTGTTG
AATACTTGGCGACGACGGGAAAACCTTAGTG
GCACCAACTAAGTTTTCTG
ATGCTCAAGCTTCGATGATGGCGGCAGCTCCCATTC
AGACCTGCTGTGCTGTTG
ATGCTCAAGCTTCGATGATGGCGGCAGCTCCCATTC
GCACCAACTAAGTTTTCTG
ATGCTCAAGCTTCGATGATGGCGGCAGCTCCCATTC
GCACCAACTAAGTTTTCTG
ATGCTCAAGCTTCGATGATGGCGGCAGCTCCCATTC
GCACCAACTAAGTTTTCTG
AATCATCGGCGACGACGGCCAGACCATCCAAGCTTCG
GAGCCGGCGGCGTAGCTG
GATCATCGGTGACGACGGAGCGACCGTGAAGG
AGTCCTGCCGTGCTGTTG
CATCCTGGGCGACGACGGCAAGACGCTGG
GCCCCCACCAGGTTCTCG
AGCTTCGAATTCTATGGAGCCCGAGGCCCCGG
AGTCCTGCCGTGCTGTTG
AGCTTCGAATTCTATGGAGCCCGAGGCCCCGG
GCCCCCACCAGGTTCTCG
AGCTTCGAATTCTATGGAGCCCGAGGCCCCGG
GCCCCCACCAGGTTCTCG
AGCTTCGAATTCTATGGAGCCCGAGGCCCCGG
GCCCCCACCAGGTTCTCG

Table 4. List of all the forward and reverse primers used to clone other minigene
and cDNA constructs used in this study
Construct Name
mSnap25 minigene
mPtbp2
mRbfox1
mMbnl2

Forward(F)/Reverse(R) Promers Primer Sequence
mSnap25_I4F1_XhoI
mSnap25_I5R1_BamHI
mPtbp2_F_AgeI
mPtbp2_R_SalI
RbFox1_F1_XhoI
RbFox1_R1_SalI
Mbnl2_F1_XhoI
Mbnl2_R1_SalI

ACAGTGCTCGAGCTTGCAGTTTCCCCAACTTGGT
ACAGTGGGATCCATCTGAGCGACTGCTTCCTGTTAG
ACAGTGACCGGTATGGACGGAATTGTCACTGAGGT
ACAGTGGTCGACTTAGATTGTTGACTTGGAGAAAGACACTCTCAG
ACAGTGCTCGAGCTAATTGTGAAAGAGAGCAGCTGAGG
ACAGTGGTCGACTTAAGTGGCACCAACGCCG
ACAGTGCTCGAGCTGCCTTGAACGTTGCCCC
ACAGTGGTCGACTTACTTAAGTTTCAGAATTATCTGATTGGCTGTGG
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Table 5. List of all the forward and reverse primers used to detect spliced isoforms
of Agrin, Snap25, Dcc minigenes by semi-quantitative RT-PCR analysis
Minigenes

RT-PCR primers(F-Forward, R=Reverse)
pCI_RT_F
Ciona Agrin
pCI_RT_R
V1_F
Mouse Snap25
V2_R
mAgr_31F2
Mouse Agrin
3xFLAG_R
mDcc_E16F1
Mouse Dcc
mDcc_E17R1

Sequence
PCR cycles
GTGTCCACTCCCAGTTCAATTACAG
27
TGTCTGCTCGAAGCATTAACCC
TCTGAGTCACCTGGACAACC
35
ATCTCAGTGGTATTTGTGAGC
TTTGATGGGCGGACCTACATCG
30
GCCGTCGTGGTCTTTGTAGTCTCTA
TCTCATTATGTAATCTCCTTAAAAGC
30
CTGCCCAGCTGACCCTCACAG

Anealing temperature
60℃
55℃
60℃
52℃

Table 6. Co-transfection protocol of minigene and splicing factor cloned in pCi-neo
and pEGFP-C1 vector respectively
pCi-neo_minigene (µL)
pEGFP_Splicing factor (µL)
pEGFP-C1_Empty vector (µL)
Total DNA (µg)
PEI (µL)
Opti-MEM (µL)

1x = 0.5 µg
0x = 0.0 µg
4x = 2.0 µg
2.5 µg
7.5 µL
Upto 200 µL

1x = 0.5 µg
1x = 0.5 µg
3x = 1.5 µg
2.5 µg
7.5 µL
Upto 200 µL

1x = 0.5 µg
4x = 2.0 µg
0x = 0.0 µg
2.5 µg
7.5 µL
Upto 200 µL

Table 7. Co-transfection protocol of minigene and splicing factor cloned in pSPL3
and pCAGGS-3x-Flag vector respectively
pSP_minigene (µL)
pCAGGS_Splicing factor (µL)
pcDNA3_Empty vector (µL)
Total DNA (µg)
PEI (µL)
Opti-MEM (µL)

1x = 0.5 µg
0x = 0.0 µg
4x = 2.0 µg
2.5 µg
7.5 µL
Upto 200 µL

1x = 0.5 µg
1x = 0.5 µg
3x = 1.5 µg
2.5 µg
7.5 µL
Upto 200 µL
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1x = 0.5 µg
4x = 2.0 µg
0x = 0.0 µg
2.5 µg
7.5 µL
Upto 200 µL

10 μm
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Figure 1. Cloning and characterization of Nova and Agrin from Ciona robusta.
(A, B) Full-length (FL) Nova and Agrin from larvae at 22.5 hpf at 20° C and adult brain
were detected by semi-quantitative RT-PCR. FL Agrin and Nova are approximately 8
kilobases and 2 kilobases, respectively. (C) Detection of all the possible Z isoforms (Z+
and Z-) of Agrin from Ciona adult brain and larvae at 22.5 hpf at 20° C by semiquantitative RT-PCR. (D) Amino acid (AA) sequence alignment of different CiNova
isoforms; the isoforms are named after the first 3 AA. Alternative first exon 1a usage by
CiNova_MMM is highlighted as purple with NLS bolded and shown in yellow. Usage of
alternative exon 1b by CiNova_MLN and CiNova_MEY is highlighted as light gray; both
isoforms lack a canonical NLS. CiNova_MLN and CiNova_MEY use different starting
AUG codons from the same pre-mRNA. Asterisks represent missing AA from CiNova
MEY and hyphens represent sequence identity beside KH domains. The KH1, KH2, and
KH3 domains are highlighted as yellow, green, and turquoise, respectively. The GXXG
motifs present in each KH domain are bolded and shown in red.
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Figure 2. Nova promotes inclusion of Agrin’s Z exons in a dose-dependent manner.
(A, B) Schematic illustration of Ciona Agrin minigenes containing the genomic region
between exons 40 and 41 in Ciona, and exons 31 and 33 in mouse. The constitutive exons
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(exon 40 and 41 in Ciona; exon 31 and 34 in mouse) are shown in dark blue, the
alternative Z exons (Z6 and Z5 in Ciona; exon 32/Z8 and 33/Z11 in mouse) are shown in
red. Thick lines between exons represent introns. Intron and exon sizes are shown in
nucleotides. (C) Schematic representation of Nova protein structure. Nova harbors 3 KH
RNA-binding domains and a spacer sequence in between KH2 and KH3. N/C-terminus
and GXXG motifs in each KH domain are also shown. (D) CiAgrin minigene splicing
assay. Constant amounts of Ciona Agrin (0.5 g/well; 1x) minigene were co-transfected
in HEK293T cells in 6-well plates with increasing amounts of EGFP-CiNova (0 g = 0x,
0.5 g = 1x, 2 g = 4x) constructs (MMM, MLN, and MEY). Total RNA was extracted
48h after transfection and subjected to semi-quantitative RT-PCR analysis. All 3 CiNova
isoforms are able to promote inclusion of CiAgrin’s Z exons in a dose-dependent manner,
giving rise to Z11 (Z6+Z5) and Z5 splice forms. The identity of the RT-PCR products
was confirmed by cloning and direct sequencing. (E) The expression of all 3 EGFPCiNova protein was detected by western blotting. All 3 EGFP CiNova constructs were
co-transfected with CiAgrin minigene in HEK293T cells as in D. The anti-EGFP
antibody recognizes both EGFP-CiNova and EGFP from EGFP-C1 empty vector. All 3
EGFP-CiNova proteins were robustly expressed in a dose-dependent manner. (F) AS of
mouse Agrin minigene and 2 cDNA constructs of mNova. Only Z8 isoform of mouse
Agrin was detected by semi-quantitative RT-PCR when mouse Agrin minigene was
individually co-transfected with mNova1 and mNova2. mNova promotes inclusion of Z8
exon of mouse Agrin in a dose-dependent manner. (G) mRbfox1 strongly promotes
inclusion of Z exons. Z8 and Z19 isoforms of Z+ Agrin were detectable by RT-PCR. (H)
Schematic representation of the genomic region of Dcc between exons 16 and 17 used to
generate a minigene construct. Intron and exon sizes are shown in nucleotides.
Constitutive exons are shown as dark blue boxes, while an alternative version of exon 17
is shown as a red box. Use of an alternative 3’ splice site at exon 17 gives rise to a longer
version of Dcc. Thick lines between exons represent introns. (I) Total RNA from
HEK293T cells co-transfected with mDcc minigene and mouse Nova1 or Nova2 was
extracted and subjected to semi-quantitative RT-PCR analysis. Both Nova1 and Nova2
promote the usage of the distal 3’ splice site and the generation of the Dcc long isoform
in a dose-dependent manner.
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Figure 3. Expression of CiAgrin’s Z isoforms is developmentally regulated.
Total RNA from unfertilized eggs and embryos at different developmental stages (hpf at
20° C), plus brain and heart from adult animals, was extracted and subjected to semiquantitative RT-PCR analysis using gene-specific primers. Primers located in constitutive
exon 40 and 41 surrounding the Z site detect all isoforms of CiAgrin. While Agrin is
robustly expressed in all samples analyzed including unfertilized eggs, Z+ isoforms start
to be expressed at 10 hpf and later stages, including adult brain, with strongest expression
in swimming larvae (top panel).This result was confirmed using primers that specifically
detect the Z11 (Z6+Z5) isoform of CiNova, with strongest expression in swimming
larvae (second panel). CiNova is expressed at low levels in fertilized eggs and adult heart,
and robustly throughout Ciona larval development (third panel). Actin was used as
internal control as it is robustly in all samples analyzed (fourth panel). 5.5 hpf at 20° C:
Late gastrula/early neurula; 7.5 hpf at 20° C: Tailbud; 22.5 hpf at 20° C: Swimming
larvae.
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Figure 4. CiNova requires both KH1 and KH2 domains for splicing.
(A) Schematic representation of CiNova protein. Its 3 KH domains are labeled in
different colors. GXXG motifs (green) present in WT protein were mutated to GDDG
(dark red). (B) CiAgrin minigene splicing assays were performed in HEK293T cells as
described in Figure 2, using WT and single KH GDDG mutants of CiNova. WT CiNova
promotes inclusion of Agrin’s Z exons, while KH1 and KH2 GDDG mutants failed to
promote Z exons inclusion. KH3 GDDG mutant is indistinguishable from WT. (C)
CiAgrin minigene splicing assay using WT and double/triple KH GDDG mutants.
Double and triple KH GDDG mutants fail to promote inclusion of Agrin‘s Z exons.
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Figure 5. Novel function of N/C-terminals and KH3 domain of CiNova.
HEK293T cells were co-transfected with CiAgrin minigene and CiNova WT and
7different deletion mutants. (A) AS of WT CiNova and its 4 deletion mutants: ΔN-ter,
ΔC-ter, ΔNΔC-ter, and ΔKH3. All these deletion mutants are unable to promote inclusion
of Agrin’s Z exons with the exception of ΔKH3 mutant, which is indistinguishable from
WT. (B) Minigene splicing assay of WT CiNova and N/C-ter deletion mutants coupled
with KH3 deletion. Surprisingly, deletion of KH3 rescues the splicing defects of N/C-ter
deletion mutants.
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Figure 6. Alternative splicing of CiAgrin with WT and mutant CiNova_MMM
constructs.
(A) CiAgrin minigene splicing assays were performed in HEK293T cells as described in
Figure 2 (except 4x Nova transfection was omitted), using WT and single KH GDDG
mutants of CiNova. Cells were co-transfected with constant amounts of Ciona Agrin
minigenes and increasing amounts of CiNova (WT vs. KH GDDG mutants). Total RNA
was extracted and subjected to semi-quantitative RT-PCR analysis. WT CiNova
promotes inclusion of Agrin’s Z exons, while KH1 and KH2 GDDG mutants failed to
promote Z exons inclusion. KH3 GDDG mutant is indistinguishable from WT. (B)
CiAgrin minigene splicing assay using WT and double/triple KH GDDG mutants.
Double and triple KH GDDG mutants fail to promote inclusion of Agrin‘s Z exons. (C)
Alternative splicing of WT CiNova_MMM and its 3 deletion mutants: ΔN-ter, ΔC-ter,
and ΔNΔC-ter. All these deletion mutants are unable to promote inclusion of Agrin’s Z
exons. (D) Minigene splicing assay of KH3 deletion and N/C-ter deletion mutants
coupled with KH3 deletion. KH3 deletion mutant is indistinguishable from WT in its
ability to promote splicing of the Z exons. Deletion of KH3 rescues the splicing defects
of N/C-ter deletion mutants.
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Figure 7. Mouse Nova2 requires its third KH3 domain to splice mouse Agrin.
(A, C) Mouse Agrin minigene splicing assays were performed in HEK293T cells as
described in Figure 2, using WT and KH GDDG mutants of mNova1 (A, B) and Nova2
(C, D). Cells were co-transfected with constant amounts of mouse Agrin minigenes and
increasing amounts of Nova (WT vs. KH GDDG mutants). Total RNA was extracted and
subjected to semi-quantitative RT-PCR analysis. (A) The expected Z8 isoforms were
detected when mouse Agrin minigene was co-transfected with WT and single KH GDDG
mutants of Nova1. (B) Double and triple KH GDDG mutants of Nova1 completely
abolish splicing of Z exons of mouse Agrin, suggesting that all 3 KH domains of Nova1
cooperate to splice Agrin. (C) The expected Z8 isoforms were detected when mouse
Agrin minigene was co-transfected with WT and single KH1 and KH2 GDDG mutants of
Nova2, while Nova2 KH3 GDDG mutant is unable to splice mouse Agrin. (D) The
expected Z8 isoforms were detected when mouse Agrin minigene was co-transfected
with WT Nova2, but double and triple KH GDDG mutants of Nova2 completely abolish
splicing of Z exons of mouse Agrin, suggesting that Nova2 primarily uses KH3 to splice
Agrin, but KH1 and KH2 also contribute to its splicing activity.
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Figure 8. Exonic YCAY sequences are not required for Nova-dependent inclusion of
Agrin’s Z exons, while a bipartite Nova-dependent intronic splicing enhancer
mediates inclusion of Agrin’s Z exons.
(A) Schematic illustration of Ciona Agrin minigene containing the genomic region
between exons 40 and 41. The constitutive exons (exon 40 and 41) are shown in dark
blue color and the alternative Z exons (Z5 and Z6) are shown in red color. YCAY
(Y=C/U) sequences (black bars indicate YCAY sequence) are bona fide Nova binding
sequences and are exclusively located downstream of exon Z5 and within exons 40 and
41. Two clusters of YCAY sequences (red lines downstream of exon Z5) are the Nova
binding sites and are called Nova intronic splicing enhancer 1 and 2 (NISE1, YCAY1-6
and NISE2, YCAY11-14. (B) CiAgrin minigene splicing assays were performed in
HEK293T cells as described in Figure 2 using WT and exonic YAAY mutant CiAgrin
minigenes and WT CiNova. Exonic YAAY mutations don’t abolish splicing, suggesting
that exonic YCAY sequences are not required for splicing. *: RT-PCR products form
exon 41 mutants run aberrantly on agarose gel. (C, D) CiAgrin minigene splicing assays
were performed using WT and 3 NISE1 (C) and NISE 2 (D) YAAY mutants with WT
CiNova. For CiNova to effectively splice Z exons of CiAgrin, at least two consecutive
YCAY sequences from each NISE clusters are needed. Single YAAY CiAgrin mutants
are indistinguishable from WT, while double YAAY mutants are unable to include
CiAgrin’s Z exons. (E) Two NISE YCAY clusters are required for CiNova to promote
splicing of CiAgrin’s Z exons. Heat map represents the Nova-dependent splicing activity,
where a green rectangle means splicing is active and a red rectangle means splicing is
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abolished. X axis represents the position and number of YCAY sequences on exon 40,
intron 40, and exon 41. Y axis represents all 32 YAAY mutant minigenes of CiAgrin (3
exonic and 29 intronic) generated in this study. Two NISE clusters (NISE1, YCAY1-6
and NISE2, YCAY11-14) of YCAY sequences are critical for CiNova-dependent
splicing of CiAgrin’s Z exons. Single YAAY mutations from either NISE clusters cannot
disrupt splicing but two or more than two mutations in YCAY completely abolish
splicing, suggesting that 2 is the minimum number of YCAY sequences required in each
cluster to be splicing-competent. (F) Spacing between the YCAY sequences does not
appear to be critical for splicing.
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Figure 9. Splicing of Z exons of Agrin is species-specific.
(A) Total RNA from HEK293T cells co-transfected with CiAgrin minigene and Nova
from either Ciona or mouse was extracted and subjected to semi-quantitative RT-PCR
analysis as described in Figure 2. CiNova promotes inclusion of the Z exons of CiAgrin
but mouse Nova cannot splice the Z exons of Ciona Agrin. (B) Total RNA from
HEK293T cells co-transfected with mouse Agrin minigene and Nova from either mouse
or Ciona extracted and subjected to semi-quantitative RT-PCR analysis. Mouse Nova
promotes inclusion of the Z exons of mouse Agrin, while CiNova cannot splice the Z
exons of mouse Agrin.
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Figure 10. A model of CiNova protein action on CiAgrin pre-mRNA.
KH1 and KH2 domains of Nova interact with NISE1 and NISE2 on CiAgrin’s premRNA, (respectively or vice versa). The KH3 domain is a negative regulator of Agrin’s
splicing, while both N- and C-terminus domains block the inhibitory activity of KH3. We
suggest that Nova in Ciona may regulate splicing using two different modalities: one
mode requires KH1 and KH2 domains to regulate AS of targets such as Agrin; the other
mode requires the KH3 domain to regulate AS of other, yet to be identified non-Agrin
targets. The N/C-terminus domain acts as a regulatory switch between the two splice
modalities.
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Figure 11. Nova1, Nova2, Ptbp2, and Rbfox1 regulate alternative splicing of Snap25.
HEK293T cells were co-transfected with constant amount of mSnap25 (1x) and 5
different splicing factors including mNova1/2, mPtbp2, mRbfox1, and mMbnl2.
Different amounts of splicing factor (0 g = 0x, 0.5 g = 1x, 2 g = 4x) were used. (A)
Schematic illustration of mSnap25 minigene cloned into pSPL3 exon trapping vector.
Vector exons V1 and V2 are depicted as dark blue boxes and alternative exons 5a/5b of
mSnap25 are shown in red boxes. The thick dark line represents the introns of mSnap25,
and the thin line represents the vector intron. The sizes of intronic and exon regions from
Snap25 genomic region are indicated. The location of the restriction sites NdeI on exon
5a and AvrII on exon 5b are indicated, alongside the restriction sites used for cloning. (B)
Minigene splicing assay of mSnap25 minigene and 5 expression constructs of mNova1,
mNova2, mPtbp2, mRbfox1, and mMbnl2. A dose-dependent inclusion of alternative
5a/5b exons was detected by semi-quantitative RT-PCR (*shadow band of 5a/5b) in all
samples. (C, D, E, F, G) Total RNA from HEK293T cells were extracted after cotransfection with mSnap25 minigene and subjected to semi-quantitative RT-PCR
analysis. RT-PCR products were digested with NdeI and AvrII to determine which exon
inclusion is promoted by mNova1, mNova2, mRbfox1, mMbnl2, and mPtbp2. If exon 5a
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is included, digestion of the RT-PCR products with the exon 5a-specific restriction
enzyme NdeI generates two fragments of 194 and 186 bp; conversely, if exon 5b is
included, digestion of the RT-PCR products with the exon 5b-specific restriction site
AvrII generates two fragments of 211 and 171 bp. (C) mNova1 very weakly promotes the
inclusion of both 5a and 5b in a dose-dependent manner, while mNova2 (D) and
mRbfox1 (E) promotes the inclusion of 5b and skipping of 5a of mSnap25 in a dosedependent manner. (F) mPtbp2 only promotes the inclusion of 5a of mSnap25 minigene
(G) mMbln2 regulates inclusion of both exons but the inclusion of 5a is stronger than 5b.
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Figure 12. Competition between splicing factors determines splicing outcome of 5a
and 5b of mSnap25.
(A, B, C, D, E, F) HEK293T cells were co-transfected with mSnap25 minigene and 2
different splicing factors (one with varying amounts and other one with constant amount).
Total RNA was extracted 48 hours after transfection and subjected to semi-quantitative
RT-PCR analysis. RT-PCR products were digested with NdeI and AvrII to determine
which exon inclusion or skipping is promoted by each splicing factor. (A) RT-PCR
analysis of cells co-transfected with constant amounts of mPtbp2 in combination with
increasing amounts of mRbfox1. mRbfox1 promotes inclusion of 5b when competing
with mPtbp2 for mSnap25 splicing. (B) mPtbp2 promotes the inclusion of 5a and
skipping of 5b in a dose-dependent manner when competing with constant amount of
mRbfox1. (C) mNova1 promotes skipping of 5b in a dose-dependent manner when
competing with constant amount of mRbfox1. (D) mRbfox1 promotes inclusion of 5b
when competing with constant amount of mNova1. (E, F) No competition is observed
between mRbfox1 and mNova2.
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CHAPTER 3

INVESTIGATING HOW MUTATIONS IN SLC25A10
MAY AFFECT SPLICING IN A PATIENT WITH
EPILEPTIC ENCEPHAPLOPATHY
3.1 ABSTRACT
Mitochondrial diseases are a plethora of inherited neuromuscular disorders
sharing defects in mitochondrial respiration, but largely different from one another for
genetic basis and pathogenic mechanism. The laboratory of Dr. De Grassi performed
whole exome sequencing in a familiar trio (trio-WES) with a child affected by severe
epileptic encephalopathy associated with respiratory complex I deficiency and
mitochondrial DNA depletion in skeletal muscle. By trio-WES they identified biallelic
mutations in SLC25A10, a nuclear gene encoding a solute carrier protein that transports
molecules for Kreb’s cycle and is a part of complex I in mitochondria. The patient
inherited 3 mutations from his parents: 1 from his mother and 2 from his father. The
maternal-derived mutation introduces a stop codon in exon 3. Mutations from the
paternal allele are located in exon 9 and intron 10. Although the exonic mutation is a
synonymous mutation, the patient had very low levels of SLC25A10 mRNA and was
devoid of protein. Using minigene splicing studies, we discovered that paternal-derived
mutations cause aberrant splicing, providing evidence for the mechanism that leads to the
failure to make a functional protein product in the patient. Our work underlies the
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importance of splicing in neurodegenerative disorders and proposes a molecular
mechanism that explains disease pathology.

3.2 BACKGROUND
The mitochondrial respiratory complex I couples the transfer of electrons from
NADH to ubiquinone and the translocation of protons from the mitochondrial matrix to
the intermembrane space, contributing to oxidative phosphorylation. Clinical presentation
of complex I deficiency is extremely heterogeneous, ranging from fatal neonatal disease
to adult-onset neurodegenerative disorders (Fassone et al., 2012), and often associates to
epilepsy (Khurana et al., 2008). The vast genetic heterogeneity of isolated complex I
deficiency is caused by mutations in mitochondrial DNA (mtDNA) or, in most cases, in
nuclear-DNA genes encoding structural subunits, assembly factors, or other proteins with
apparently complex I unrelated functions (see OMIM 252010). Further, the activity of
complex I is susceptible to environmental factors, such as oxidative stress (Musatov et
al., 2012). SLC25A10 (also known as DIC) transports dicarboxylates and phosphate
across the inner mitochondrial membrane and is conserved from yeast to mammals
(Palmieri et al., 1996; Fiermonte et al., 1998). As reviewed in (Lash et al., 2015),
SLC25A10 inhibition has been repeatedly reported to cause reduced levels of
mitochondrial glutathione (GSH) and impairment of complex I activity in rat neurons
(Kamga et al., 2010). Here we report the first human mutations abolishing SLC25A10
function in a patient affected by a progressive form of epileptic encephalopathy and
severe hypotonia associated with complex I deficiency.
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3.2.1 Case description
This study was approved by the Pediatric Ethics Committee of the Tuscany
Region, Italy (in the context of the Project DESIRE) and informed consent was signed by
the patient’s parents. The proband is a 9-year-old boy born at term from
nonconsanguineous healthy parents of two additional healthy children. Hypospadias,
bilateral hydrocele and unilateral right hearing loss were noticed in the patient. At 3
months, generalized jerking and infantile spasms appeared in multiple per day episodes.
Clinical examinations showed severe hypotonia, absent eye tracking and poor
spontaneous movements. EEG revealed multifocal epileptiform discharges and a
suppression burst pattern. MRI, initially normal, showed high signal intensity of the
white matter at 1 year and also thinning of the CC at 4 years of age. Clinical conditions
evolved in intractable tonic spasms and focal seizures and quadriparesis, which
progressively became spastic and dyskinetic. Growth parameters have always been
within the normal range and neuropsychiatric evaluations revealed intellectual ability in
the normal-high range. Multiple metabolic investigations, cerebrospinal-fluid amino
acids, neurotransmitter levels and visual evoked potentials were normal. Blood analyses
revealed microcytic anemia, which was improved after iron supplementation, and
increased lactate (3.64 mM) and lactate/pyruvate (25.58) levels. The analysis of the four
mitochondrial respiratory complexes from muscle homogenates, performed at 18 months,
indicated reduced respiratory complex I activity (27% of the mean control value) and
decreased mtDNA content (40% lower than the mean control value). Multiple
antiepileptic drug trials and ketogenic diet were ineffective against seizures.
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3.2.2 Compound heterozygous mutations in SLC25A10
Pathogenic mutations in the mitochondrial genome were excluded by Sanger
sequencing. Three independent whole exome sequencing experiments (trio-WES) were
performed on the genomic DNA of the patient and his parents. Compound heterozygous
mutations were identified in SLC25A10. A heterozygous SLC25A10 nonsense mutation
was inherited from the mother (NM_001270888.1: c.304A>T, p.Lys102*, Fig.). This
mutation, absent in the ExAC database (September 2017), generates a prematurely
truncated protein lacking ~70% of the amino acid sequence. Two heterozygous mutations
were inherited from the father: a synonymous mutation (NM_001270888.1: c.684C>T,
p.Pro228Pro) annotated in the dbSNP146 database (rs114621664) with frequency of
0.0014 in the ExAC database and an intronic mutation (NM_001270888.1: c.790–
37G>A) annotated in the dbSNP146 database (rs200706742) with frequency of 0.0011 in
the ExAC database. Mutations have been submitted to the NCBI ClinVar database
(www.ncbi.nlm.nih.gov/clinvar/, accessions SCV000611119 and SCV000611120).
The quantitative Real Time-PCR (qRT-PCR) analysis, conducted on cDNA obtained
from cultured fibroblasts, showed a 10-fold decrease in SLC25A10 transcript level in the
patient relative to control. PCR primer-pairs were designed to amplify two distinct
portions of the SLC25A10 cDNA, which span exons 3–8 and exons 3–11, respectively.
The former was detected in both the patient and control. The sequence of this fragment
corresponds to the paternally inherited allele, suggestive of nonsense mediated decay of
the maternally inherited one. The fragment spanning exons 3–11 is instead virtually
absent in the patient cells, suggesting abnormal RNA splicing in-between exons 9 and 11.
The paternally inherited mutations are predicted to break an exon splicing enhancer in
exon 9 and to create a new one in intron 10, respectively.
78

3.3 MATERIALS AND METHODS
3.3.1 Transfection with SLC25A10 minigene
The day before the transfection 0.6 x 106 HEK293T cells were seeded per well in
a 6-well plate (USA Scientific). On the day transfection, a total of 1 g DNA of
SLC25A10 minigene was used to transfect each of 6 well plate(s) and 3 L of PEI
(1mg/mL) was used in a ratio of 1:3 (DNA : PEI). The total volume of the DNA mixture
was 200 L. First, the exact amount of DNA in L was pipetted in 1.5 mL Eppendorf
tube (Eppendorf) and Opti-MEM media was used to bring the volume to 197 L. Then
the mixture was vortexed thoroughly. Finally, 3 L of PEI were added, vortexed, and
centrifuged briefly. The mixture was then incubated for 15 minutes at room temperature.
In the meantime, medium in the cells was aspirated and 2 mL new DMEM medium was
added. After 15 minutes of incubation 200 L of reaction mixture was added to the cell
and the plate was cross-shanked gently. The plate was then Incubated for 48 hours at 37 °
C.
For other materials and methods please refer to “2.2 MATERIALS AND
METHODS” section in Chapter 2.
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3.4 RESULTS
3.4.1 SLC25A10 mutations cause RNA depletion and aberrant RNA splicing
To investigate if paternally derived mutations lead to aberrant splicing, 5 pair of
WT and mutant minigenes were generated (Fig. 13J) containing the genomic region of
SLC25A10 encompassing flanking exons/introns. The mutant minigenes include the
intronic mutation (G>A) alone (with and without 3 UTR), the exonic mutation (C>T)
alone, and both intronic and exonic mutations together. The genomic region was
amplified by PCR and cloned into the mammalian expression vector pCi-neo. We
transfected constant amounts of our minigene construct in triplicate in HEK293T cells.
Total RNA was extracted, quantified, normalized and subjected to semi-quantitative RTPCR analysis.
Our splicing data revealed a change in splicing pattern for the intronic mutation
alone (with and without 3 UTR) (Fig.13B, D) but not for the synonymous exonic
mutation alone (Fig.13F), suggesting a primary role of the intronic mutation in inducing
aberrant RNA splicing. Intriguingly, however, splicing was severely disrupted in a
minigene hosting both exonic and intronic mutations (Fig.13H): the exonic mutation
alone has no effect but it appears to exacerbate the effect of intronic mutation, thus
having an additive effect on aberrant pre-mRNA splicing. RT-PCR quantification of
RNA splicing isoforms showed that mutant SLC25A10 promotes a shift toward shorter
splicing isoforms, thus favoring the exclusion of both exon 10 and intron 10, when
compared with the WT allele (Fig.13I). Our splicing investigation on the paternallyderived mutant SLC25A10 allele provides a convincing explanation for the absence of
protein in the patient.
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3.5 DISCUSSION
Here, we used our functional minigene splicing assay to explain disease pathology
in a patient with severe epileptic and progressive encephalopathy. The proband inherited
3 mutations from his parents including 1 from his mother and 2 from his father. The
maternal-derived mutation introduces a stop codon in exon 3, while parental-derived
mutations are located in exon 9 and intron 10. Although the exonic mutation is a
synonymous mutation, the patient had very low levels of SLC25A10 mRNA and was
devoid of protein. Using minigene splicing assays, we showed that the mutant DNA
promotes a shift toward shorter splicing isoforms, thus favoring the exclusion of
SLC25A10 exon 10 and intron 10, when compared with the wild-type (Fig. 13H, I). The
RNA quantitative change was also observed in other minigene hosting the intronic
mutation alone (Fig. 13B, D), but not in minigene hosting the synonymous mutation
alone (Fig. 13F), however, the effect of exonic mutation exacerbate the effect of intronic
mutation, suggesting a primary role of the intronic mutation in inducing the aberrant
RNA splicing (Fig. 13H). Our work underlies the importance of splicing in
neurodegenerative disorders and proposes a molecular mechanism that explains disease
pathology.

3.6 CONCLUSIONS AND PERSPECTIVES
In summary, we report first SLC25A10 recessive disease-causing mutations
associated with abnormal splicing. Albeit additional SLC25A10 mutations in unrelated
individuals will be required as standard proof of causality. Further work is warranted to
exploit the SLC25A10-mediated molecular mechanisms that protect cellular respiration
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and redox state. An interesting future project would be do design antisense
oligonucleotides to restore the expression of correct isoform of SLC25A10.
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3.7 TABLES AND FIGURES
3.7.1 TABLES
Table 8. List of all the forward and reverse primers used to clone SLC25A10
minigene constructs used in this study
Construct Name
SLC25A10
SLC25A10
SLC25A10
SLC25A10
SLC25A10

Forward(F)/Reverse(R) Promers Primer Sequence

SLC25A10_E9F1_XhoI
244 nt minigene
SLC25A10_E11R1_XbaI
SLC25A10_E9F1_XhoI
600 nt minigene
SLC25A10_E11R2_XbaI
SLC25A10_I8F1
2131 nt minigene
SLC25A10_E10R1_XbaI
SLC25A10_I8F2
2320 nt minigene
SLC25A10_E11R1_XbaI
SLC25A10_E8F1_XhoI
2489 nt minigene
SLC25A10_E10R1_XbaI

ACAGTGCTCGAGGCCGCTGGTGACGAGC
ACAGTGTCTAGAGGATGGCACTTTGATGCCAAAG
ACAGTGCTCGAGGCCGCTGGTGACGAGC
ACAGTGTCTAGACCTCGATGGAAAGTGCTGGAAGAT
TAGGAGTCAGGTGGAGGTTCTGG
ACAGTGTCTAGACTTGTAAAAGGCCAGAGGCCC
TAAGTGGCCGGCATGGCTA
ACAGTGTCTAGAGGATGGCACTTTGATGCCAAAG
ACAGTGCTCGAGCTGTCCTGCTACGACCAGG
ACAGTGTCTAGACTTGTAAAAGGCCAGAGGCCC
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Figure 13. A functional splicing analysis for SLC25A10 minigenes.
(A, C, E, G) Schematic representations of the minigene constructs; minigenes are named
based on the number of nucleotides (nt) (blue box: coding sequence with exon number;
gray: 3’UTR), along with the sequence identity of the cloned DNA (WT: wild-type; Mut:
mutant). (B, D, F, H) RT-PCR analysis of total RNA extracted from HEK293T cells
transfected with specific minigenes in triplicate. The intronic mutants without (B) and
with 3’ UTR (D) promote a small change in splicing by excluding intron 10 (I10) when
compared to WT minigene. However, the minigene hosting the intronic and exonic
mutations together (G) severely disrupt the splicing program (H). (I) Ratio analysis
between the splicing fragments from figure H shows a significant reduction of I10, E11
(exon11), and E10 (exon10)-I10. Actin served as experimental control (H). No difference
is observed in the two minigenes hosting the synonymous mutation (C>T) alone (F). (J)
Table representing splicing activity of all the different combination of exonic and intronic
mutant minigenes. Splicing is severely affected when both intronic and exonic mutations
are present in the minigene. Data are presented as mean+SEM of at least three
experiments; ***: non parametric Wilcoxon test P-value<0.05.(minigene cartoons are not
drawn to scale).
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